{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T21:43:40Z","timestamp":1793915020813,"version":"4.8.0"},"reference-count":346,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T00:00:00Z","timestamp":1713225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Sj\u00f6gren disease (SD) is a chronic, autoimmune disease of unknown aetiology with significant impact on quality of life. Although dryness (sicca) of the eyes and mouth are the classically described features, dryness of other mucosal surfaces and systemic manifestations are common. The key management aim should be to empower the individual to manage their condition\u2014conserving, replacing and stimulating secretions; and preventing damage and suppressing systemic disease activity. This guideline builds on and widens the recommendations developed for the first guideline published in 2017. We have included advice on the management of children and adolescents where appropriate to provide a comprehensive guideline for UK-based rheumatology teams.<\/jats:p>","DOI":"10.1093\/rheumatology\/keae152","type":"journal-article","created":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T00:40:07Z","timestamp":1713228007000},"page":"409-439","source":"Crossref","is-referenced-by-count":74,"title":["British Society for Rheumatology guideline on management of adult and juvenile onset Sj\u00f6gren disease"],"prefix":"10.1093","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3042-0201","authenticated-orcid":false,"given":"Elizabeth J","family":"Price","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Great Western Hospital NHS Foundation Trust , Swindon,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Benjamin","sequence":"additional","affiliation":[{"name":"The Academy Library and Information Service, Great Western Hospital NHS Foundation Trust , Swindon,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Bombardieri","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Barts and The London School of Medicine and Dentistry, Barts Health NHS Trust , London,","place":["UK"]},{"name":"Centre for Experimental Medicine and Rheumatology, The William Harvey Research Institute, Queen Mary University of London , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Bowman","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Milton Keynes University Hospital , Milton Keynes,","place":["UK"]},{"name":"Department of Rheumatology, University Hospitals Birmingham NHSFT , Birmingham,","place":["UK"]},{"name":"Institute of Inflammation and Ageing, University of Birmingham , Birmingham,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Carty","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Great Western Hospital NHS Foundation Trust , Swindon,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8911-4113","authenticated-orcid":false,"given":"Coziana","family":"Ciurtin","sequence":"additional","affiliation":[{"name":"Centre for Rheumatology, Division of Medicine, University College London , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bridget","family":"Crampton","sequence":"additional","affiliation":[{"name":"Patient Representative, Sjogren\u2019s UK Helpline Lead, Sjogren\u2019s UK (British Sj\u00f6gren\u2019s Syndrome Association) , Birmingham,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annabel","family":"Dawson","sequence":"additional","affiliation":[{"name":"Patient Representative, Sjogren\u2019s UK (British Sj\u00f6gren\u2019s Syndrome Association) , Birmingham,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4631-549X","authenticated-orcid":false,"given":"Benjamin A","family":"Fisher","sequence":"additional","affiliation":[{"name":"Rheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham , Birmingham,","place":["UK"]},{"name":"National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre and Department of Rheumatology, University Hospitals Birmingham NHS Foundation Trust , Birmingham,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Giles","sequence":"additional","affiliation":[{"name":"Centre for Rheumatology, Division of Medicine, University College London , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Glennon","sequence":"additional","affiliation":[{"name":"General Practice, NHS Staffordshire & Stoke on Trent ICB , Stafford,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Gupta","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Gartnavel General Hospital , Glasgow,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0249-9434","authenticated-orcid":false,"given":"Katie L","family":"Hackett","sequence":"additional","affiliation":[{"name":"Department of Social Work, Education and Community Wellbeing, Northumbria University , Newcastle upon Tyne,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genevieve","family":"Larkin","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Kings College Hospital , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan-Fai","family":"Ng","sequence":"additional","affiliation":[{"name":"Translational and Clinical Research Institute & Newcastle NIHR Biomedical Research Centre, Newcastle University , Newcastle upon Tyne,","place":["UK"]},{"name":"Department of Rheumatology, Newcastle upon Tyne NHS Foundation Trust , Newcastle upon Tyne,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athimalaipet V","family":"Ramanan","sequence":"additional","affiliation":[{"name":"Department of Paediatric Rheumatology, Bristol Royal Hospital for Children , Bristol,","place":["UK"]},{"name":"Translational Health Sciences, University of Bristol , Bristol,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad","family":"Rassam","sequence":"additional","affiliation":[{"name":"Haematology and Haemato-Oncology, KIMS Hospital , Maidstone, Kent,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saaeha","family":"Rauz","sequence":"additional","affiliation":[{"name":"Ophthalmology, Institute of Inflammation and Ageing, University of Birmingham , Birmingham,","place":["UK"]},{"name":"Birmingham and Midland Eye Centre, Sandwell and West Birmingham NHS Trust , Birmingham,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Smith","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Great Western Hospital NHS Foundation Trust , Swindon,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8150-6446","authenticated-orcid":false,"given":"Nurhan","family":"Sutcliffe","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Barts Health NHS Trust , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anwar","family":"Tappuni","sequence":"additional","affiliation":[{"name":"Institute of Dentistry, Queen Mary University of London , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen B","family":"Walsh","sequence":"additional","affiliation":[{"name":"London Tubular Centre, University College London , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,4,16]]},"reference":[{"key":"2025042214240315100_keae152-B1","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1093\/rheumatology\/kex375","article-title":"The British Society for Rheumatology guideline for the management of adults with primary Sj\u00f6gren's Syndrome","volume":"56","author":"Price","year":"2017","journal-title":"Rheumatology (Oxford, England)"},{"key":"2025042214240315100_keae152-B2","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1093\/rheumatology\/keaa870","article-title":"The management of Sj\u00f6gren\u2019s syndrome: British Society for Rheumatology guideline scope","volume":"60","author":"Price","year":"2020","journal-title":"Rheumatology"},{"key":"2025042214240315100_keae152-B3","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1136\/annrheumdis-2017-eular.2823","article-title":"SAT0736-HPR \u201clike a bag of liquorice allsorts\u2014everybody's got different flavours\u201d: a qualitative focus group study to explore symptoms of fatigue, sleep disturbances and pain in primary Sj\u00f6gren's syndrome patients and to develop a future model of care","volume":"76(Suppl 2)","author":"Hackett","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2025042214240315100_keae152-B4","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/MD.0b013e318181e6af","article-title":"Primary Sjogren syndrome in Spain: clinical and immunologic expression in 1010 patients","volume":"87","author":"Ramos-Casals","year":"2008","journal-title":"Medicine"},{"key":"2025042214240315100_keae152-B5","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1093\/rheumatology\/ket349","article-title":"Systemic involvement in primary Sjogren's syndrome evaluated by the EULAR-SS disease activity index: analysis of 921 Spanish patients (GEAS-SS Registry)","volume":"53","author":"Ramos-Casals","year":"2014","journal-title":"Rheumatology (Oxford, England)"},{"key":"2025042214240315100_keae152-B6","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1093\/rheumatology\/key370","article-title":"Health-related quality of life and costs in Sjogren's syndrome","volume":"60","author":"Miyamoto","year":"2019","journal-title":"Rheumatology (Oxford, England)"},{"key":"2025042214240315100_keae152-B7","first-page":"830","article-title":"Do the European League Against Rheumatism (EULAR) Sjogren's syndrome outcome measures correlate with impaired quality of life, fatigue, anxiety and depression in primary Sjogren's syndrome?","volume":"14","author":"Omma","year":"2018","journal-title":"Arch Med Sci"},{"key":"2025042214240315100_keae152-B8","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1080\/14397595.2016.1249538","article-title":"Primary Sjogren's syndrome impact on smell, taste, sexuality and quality of life in female patients: a systematic review and meta-analysis","volume":"27","author":"Al-Ezzi","year":"2017","journal-title":"Modern Rheumatol\/Japan Rheum Assoc"},{"key":"2025042214240315100_keae152-B9","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s12905-016-0353-z","article-title":"Vision-related quality of life and psychological status in Chinese women with Sjogren's syndrome dry eye: a case-control study","volume":"16","author":"Zhang","year":"2016","journal-title":"BMC Women's Health"},{"key":"2025042214240315100_keae152-B10","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1167\/iovs.03-0915","article-title":"The relative burden of dry eye in patients' lives: comparisons to a U.S. normative sample","volume":"46","author":"Mertzanis","year":"2005","journal-title":"Invest Ophthalmol Visual Sci"},{"key":"2025042214240315100_keae152-B11","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.3899\/jrheum.141475","article-title":"Quality of Sexual Life in Women with Primary Sjogren Syndrome","volume":"42","author":"Priori","year":"2015","journal-title":"J Rheumatol"},{"key":"2025042214240315100_keae152-B12","first-page":"683","article-title":"Gynaecological symptoms and sexual disability in women with primary Sjogren's syndrome and sicca syndrome","volume":"31","author":"Maddali Bongi","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"2025042214240315100_keae152-B13","first-page":"9","article-title":"Sjogren's syndrome: clinical, cytological, histological and colposcopic aspects in women","volume":"15","author":"Capriello","year":"1988","journal-title":"Clin Exp Obstetr Gynecol"},{"key":"2025042214240315100_keae152-B14","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1093\/jsxmed\/qdad044","article-title":"Coping strategies, illness perceptions, and relationship dynamics contribute to female sexual function and sexual distress in Sj\u00f6gren's syndrome","volume":"20","author":"McCready","year":"2023","journal-title":"J Sex Med"},{"key":"2025042214240315100_keae152-B15","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1007\/s00296-020-04543-2","article-title":"Peripheral neuropathy and health-related quality of life in patients with primary Sjogren's syndrome: a preliminary report","volume":"40","author":"Jask\u00f3lska","year":"2020","journal-title":"Rheumatol Int"},{"key":"2025042214240315100_keae152-B16","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/rheumatology\/kes311","article-title":"Clinical pulmonary involvement in primary Sjogren's syndrome: prevalence, quality of life and mortality\u2014a retrospective study based on registry data","volume":"52","author":"Palm","year":"2013","journal-title":"Rheumatology (Oxford)"},{"key":"2025042214240315100_keae152-B17","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1093\/rheumatology\/kep141","article-title":"Health-related quality of life, employment and disability in patients with Sjogren's syndrome","volume":"48","author":"Meijer","year":"2009","journal-title":"Rheumatology (Oxford, England)"},{"key":"2025042214240315100_keae152-B18","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/acr.23821","article-title":"Cardiovascular morbidity and mortality in primary Sjogren's syndrome: a systematic review and meta-analysis","volume":"72","author":"Beltai","year":"2020","journal-title":"Arthritis Care Res"},{"key":"2025042214240315100_keae152-B19","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1183\/16000617.0011-2016","article-title":"Pulmonary manifestations of Sjogren's syndrome","volume":"25","author":"Flament","year":"2016","journal-title":"Eur Respir Rev"},{"key":"2025042214240315100_keae152-B20","doi-asserted-by":"crossref","first-page":"102531","DOI":"10.1016\/j.autrev.2020.102531","article-title":"Worldwide trends in all-cause mortality of auto-immune systemic diseases between 2001 and 2014","volume":"19","author":"Scherlinger","journal-title":"Autoimmun Rev"},{"key":"2025042214240315100_keae152-B21","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s10067-019-04744-6","article-title":"Survival analysis of patients with Sjogren's syndrome in Turkey: a tertiary hospital-based study","volume":"39","author":"Yazisiz","year":"2020","journal-title":"Clin Rheumatol"},{"key":"2025042214240315100_keae152-B22","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/art.39859","article-title":"2016 American College of Rheumatology\/European League Against Rheumatism Classification Criteria for Primary Sjogren's Syndrome: a consensus and data-driven methodology involving three international patient cohorts","volume":"69","author":"Shiboski","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2025042214240315100_keae152-B23","doi-asserted-by":"crossref","first-page":"9094217","DOI":"10.1155\/2018\/9094217","article-title":"Evaluation of an automated screening assay, compared to indirect immunofluorescence, an extractable nuclear antigen assay, and a line immunoassay in a large cohort of asian patients with antinuclear antibody-associated rheumatoid diseases: a multicenter retrospective study","volume":"2018","author":"Jeong","year":"2018","journal-title":"J Immunol Res"},{"key":"2025042214240315100_keae152-B24","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.reuma.2014.06.004","article-title":"Usefulness of antibodies and minor salivary gland biopsy in the study of sicca syndrome in daily clinical practice","volume":"11","author":"Santiago","year":"2015","journal-title":"Reumatol Clin"},{"key":"2025042214240315100_keae152-B25","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1034\/j.1600-0463.2001.090305.x","article-title":"Performance characteristics and clinical utility of a hybrid ELISA for detection of ANA","volume":"109","author":"Ulvestad","year":"2001","journal-title":"APMIS"},{"key":"2025042214240315100_keae152-B26","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1046\/j.1365-3083.2003.01278.x","article-title":"Modelling autoimmune rheumatic disease: a likelihood rationale","volume":"58","author":"Ulvestad","year":"2003","journal-title":"Scand J Immunol"},{"key":"2025042214240315100_keae152-B27","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1515\/cclm-2017-0905","article-title":"Screening for connective tissue disease-associated antibodies by automated immunoassay","volume":"56","author":"Willems","year":"2018","journal-title":"Clin Chem Lab Med"},{"key":"2025042214240315100_keae152-B28","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s12026-013-8416-9","article-title":"Evaluation of an automated chemiluminescent immunoassay kit for antinuclear antibodies in autoimmune diseases","volume":"56","author":"Zafrir","year":"2013","journal-title":"Immunol Res"},{"key":"2025042214240315100_keae152-B29","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.cca.2013.05.011","article-title":"Clinical performance evaluation of a novel rapid response chemiluminescent immunoassay for the detection of autoantibodies to extractable nuclear antigens","volume":"424","author":"Bentow","year":"2013","journal-title":"Clin Chim Acta Int J Clin Chem"},{"key":"2025042214240315100_keae152-B30","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1309\/AJCPX1SQXKI3MWNN","article-title":"Application of linear discriminant analysis in performance evaluation of extractable nuclear antigen immunoassay systems in the screening and diagnosis of systemic autoimmune rheumatic diseases","volume":"138","author":"Pi","year":"2012","journal-title":"Am J Clin Pathol"},{"key":"2025042214240315100_keae152-B31","first-page":"279","article-title":"ANA negative (Ro) lupus erythematosus with multiple major organ involvement: a case report","volume":"20","author":"Maraina","year":"2002","journal-title":"Asian Pac J Allergy Immunol"},{"key":"2025042214240315100_keae152-B32","first-page":"102","article-title":"How immunological profile drives clinical phenotype of primary Sjogren's syndrome at diagnosis: analysis of 10,500 patients (Sjogren Big Data Project)","volume":"36(Suppl 112)","author":"Brito-Zeron","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"2025042214240315100_keae152-B33","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s00296-020-04782-3","article-title":"IgA immunoglobulin isotype of rheumatoid factor in primary Sj\u00f6gren's syndrome","volume":"41","author":"Ma\u015bli\u0144ska","year":"2021","journal-title":"Rheumatol Int"},{"key":"2025042214240315100_keae152-B34","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1007\/s00784-018-2545-4","article-title":"Clinical and diagnostic significance of serum immunoglobulin A rheumatoid factor in primary Sjogren's syndrome","volume":"23","author":"Lee","year":"2019","journal-title":"Clin Oral Investig"},{"key":"2025042214240315100_keae152-B35","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1016\/j.clinbiochem.2013.04.020","article-title":"The accuracy of the anti-\u03b1-fodrin antibody test for diagnosis of Sj\u00f6gren's syndrome: a meta-analysis","volume":"46","author":"Hu","year":"2013","journal-title":"Clin Biochem"},{"key":"2025042214240315100_keae152-B36","doi-asserted-by":"crossref","first-page":"704193","DOI":"10.3389\/fimmu.2021.704193","article-title":"The Diagnostic Performance of Early Sj\u00f6gren's Syndrome Autoantibodies in Juvenile Sj\u00f6gren's Syndrome: the University of Florida Pediatric Cohort Study","volume":"12","author":"Thatayatikom","year":"2021","journal-title":"Front Immunol"},{"key":"2025042214240315100_keae152-B37","doi-asserted-by":"crossref","first-page":"12903","DOI":"10.3390\/ijms222312903","article-title":"Salivary biomarkers in patients with Sj\u00f6gren\u2019s syndrome-a systematic review","volume":"22","author":"Jung","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2025042214240315100_keae152-B38","doi-asserted-by":"crossref","first-page":"e000364","DOI":"10.1136\/rmdopen-2016-000364","article-title":"Salivary gland ultrasound abnormalities in primary Sj\u00f6gren's syndrome: consensual US-SG core items definition and reliability","volume":"3","author":"Jousse-Joulin","year":"2017","journal-title":"RMD Open"},{"key":"2025042214240315100_keae152-B39","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1136\/annrheumdis-2019-215024","article-title":"Video clip assessment of a salivary gland ultrasound scoring system in Sj\u00f6gren\u2019s syndrome using consensual definitions: an OMERACT ultrasound working group reliability exercise","volume":"78","author":"Sandrine","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2025042214240315100_keae152-B40","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/joim.12992","article-title":"Weight of salivary gland ultrasonography compared to other items of the 2016 ACR\/EULAR classification criteria for Primary Sj\u00f6gren\u2019s syndrome","volume":"287","author":"Jousse-Joulin","year":"2020","journal-title":"J Intern Med"},{"key":"2025042214240315100_keae152-B41","doi-asserted-by":"crossref","first-page":"1759720x20973560","DOI":"10.1177\/1759720X20973560","article-title":"Diagnostic accuracy of salivary gland ultrasound in Sj\u00f6gren's syndrome: a systematic review and meta-analysis","volume":"12","author":"Ramsubeik","year":"2020","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2025042214240315100_keae152-B42","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001503","article-title":"Normal salivary gland ultrasonography could rule out the diagnosis of Sj\u00f6gren\u2019s syndrome in anti-SSA-negative patients with sicca syndrome","volume":"7","author":"Al Tabaa","year":"2021","journal-title":"RMD Open"},{"key":"2025042214240315100_keae152-B43","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1002\/acr.24017","article-title":"Incorporation of Salivary Gland Ultrasonography Into the American College of Rheumatology\/European League Against Rheumatism Criteria for Primary Sj\u00f6gren's Syndrome","volume":"72","author":"van Nimwegen","year":"2020","journal-title":"Arthritis Care Res"},{"key":"2025042214240315100_keae152-B44","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/acr.23839","article-title":"Juvenile Sj\u00f6gren's Syndrome: clinical characteristics with focus on salivary gland ultrasonography","volume":"72","author":"Hammenfors","year":"2020","journal-title":"Arthritis Care Res"},{"key":"2025042214240315100_keae152-B45","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12969-020-00437-6","article-title":"Salivary gland ultrasound in the diagnostic workup of juvenile Sj\u00f6gren's syndrome and mixed connective tissue disease","volume":"18","author":"Krumrey-Langkammerer","year":"2020","journal-title":"Pediatr Rheumatol Online J"},{"key":"2025042214240315100_keae152-B46","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1136\/annrheumdis-2017-211250","article-title":"Ultrasonography of major salivary glands compared with parotid and labial gland biopsy and classification criteria in patients with clinically suspected primary Sj\u00f6gren's syndrome","volume":"76","author":"Mossel","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2025042214240315100_keae152-B47","doi-asserted-by":"crossref","first-page":"e0162787","DOI":"10.1371\/journal.pone.0162787","article-title":"High-grade salivary-gland involvement, assessed by histology or ultrasonography, is associated with a poor response to a single rituximab course in primary Sj\u00f6gren's syndrome: data from the TEARS randomized trial","volume":"11","author":"Cornec","year":"2016","journal-title":"PLoS One"},{"key":"2025042214240315100_keae152-B48","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1016\/j.ejrad.2011.12.034","article-title":"Diagnostic accuracy of parotid CT for identifying Sj\u00f6gren's syndrome","volume":"81","author":"Sun","year":"2012","journal-title":"Eur J Radiol"},{"key":"2025042214240315100_keae152-B49","doi-asserted-by":"crossref","first-page":"10051","DOI":"10.3390\/ijms231710051","article-title":"The diagnostic value of mri-based radiomic analysis of lacrimal glands in patients with Sj\u00f6gren's syndrome","volume":"23","author":"Muntean","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2025042214240315100_keae152-B50","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1093\/rheumatology\/kead071","article-title":"FDG-PET\/CT discriminates between patients with and without lymphomas in primary Sj\u00f6gren\u2019s syndrome","volume":"62","author":"van Ginkel","year":"2023","journal-title":"Rheumatology"},{"key":"2025042214240315100_keae152-B51","first-page":"215","article-title":"Imaging in primary Sj\u00f6gren's syndrome: the \u2018obsolete and the new\u2019","volume":"36(Suppl 112)","author":"Baldini","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"2025042214240315100_keae152-B52","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.3390\/jcm9082492","article-title":"Imaging in Primary Sj\u00f6gren's Syndrome","volume":"9","author":"van Ginkel","year":"2020","journal-title":"J Clin Med"},{"key":"2025042214240315100_keae152-B53","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12891-015-0482-9","article-title":"Clinical characteristics and biopsy accuracy in suspected cases of Sj\u00f6gren's syndrome referred to labial salivary gland biopsy","volume":"16","author":"Giovelli","year":"2015","journal-title":"BMC Musculoskelet Disord"},{"key":"2025042214240315100_keae152-B54","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1093\/rheumatology\/kel266","article-title":"Parotid gland biopsy compared with labial biopsy in the diagnosis of patients with primary Sjogren's syndrome","volume":"46","author":"Pijpe","year":"2007","journal-title":"Rheumatology (Oxford, England)"},{"key":"2025042214240315100_keae152-B55","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1007\/s10067-006-0457-1","article-title":"A follow-up study of minimally invasive lip biopsy in the diagnosis of Sj\u00f6gren's syndrome","volume":"26","author":"Teppo","year":"2007","journal-title":"Clin Rheumatol"},{"key":"2025042214240315100_keae152-B56","doi-asserted-by":"crossref","first-page":"e372","DOI":"10.4317\/medoral.20010","article-title":"The role of a labial salivary gland biopsy in the diagnostic procedure for Sj\u00f6gren's syndrome; a study of 94 cases","volume":"19","author":"van Stein-Callenfels","year":"2014","journal-title":"Med oral, Patol Oral Cirugia Bucal"},{"key":"2025042214240315100_keae152-B57","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1016\/j.joms.2017.05.021","article-title":"Minor salivary gland biopsy-an important contributor to the diagnosis of Sj\u00f6gren syndrome","volume":"75","author":"Wicheta","year":"2017","journal-title":"J Oral Maxillofac Surg"},{"key":"2025042214240315100_keae152-B58","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s00296-008-0698-1","article-title":"Diagnostic performance of minor salivary gland biopsy, serological and clinical data in Sj\u00f6gren's syndrome: a retrospective analysis","volume":"29","author":"Yazisiz","year":"2009","journal-title":"Rheumatol Int"},{"key":"2025042214240315100_keae152-B59","doi-asserted-by":"crossref","first-page":"e713","DOI":"10.4317\/jced.56562","article-title":"Local complications associated with labial salivary gland biopsy for diagnosis of Sj\u00f6gren's Syndrome: a retrospective cohort study","volume":"12","author":"Varoni","year":"2020","journal-title":"J Clin Exp Dent"},{"key":"2025042214240315100_keae152-B60","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1080\/03009742.2021.1999671","article-title":"Complications after minor salivary gland biopsy: a retrospective study of 630 patients from two Swedish centres","volume":"52","author":"Olsson","year":"2022","journal-title":"Scand J Rheumatol"},{"key":"2025042214240315100_keae152-B61","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.reuma.2012.03.006","article-title":"Frequency of complications and usefulness of the minor salivary gland biopsy","volume":"8","author":"Lida Santiago","year":"2012","journal-title":"Reumatol Clin"},{"key":"2025042214240315100_keae152-B62","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1093\/rheumatology\/ket485","article-title":"Neurological adverse events related to lip biopsy in patients suspicious for Sjogren's syndrome: a systematic review and prevalence meta-analysis","volume":"53","author":"Varela Centelles","year":"2014","journal-title":"Rheumatology (Oxford, England)"},{"key":"2025042214240315100_keae152-B63","doi-asserted-by":"crossref","first-page":"2473974x221116107","DOI":"10.1177\/2473974X221116107","article-title":"Minor salivary gland biopsy in diagnosis of Sj\u00f6gren's syndrome","volume":"6","author":"Gordon","year":"2022","journal-title":"OTO Open"},{"key":"2025042214240315100_keae152-B64","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1136\/annrheumdis-2016-210448","article-title":"Standardisation of labial salivary gland histopathology in clinical trials in primary Sjogren's syndrome","volume":"76","author":"Fisher","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2025042214240315100_keae152-B65","first-page":"173","article-title":"Patient-reported change of sensibility and pain after parotid and labial gland biopsy applied for primary Sj\u00f6gren's syndrome diagnostics: one-year follow-up study","volume":"36(Suppl 112)","author":"Delli","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"2025042214240315100_keae152-B66","first-page":"2381","article-title":"Usefulness of ultrasound guided core needle biopsy of the parotid gland for the diagnosis of primary Sj\u00f6gren's syndrome","volume":"40","author":"Zabotti","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"2025042214240315100_keae152-B67","doi-asserted-by":"crossref","first-page":"101837","DOI":"10.1016\/j.berh.2023.101837","article-title":"Lacrimal and salivary gland ultrasound\u2014how and when to use in patients with primary Sj\u00f6gren's syndrome","volume":"37","author":"Fana","year":"2023","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"2025042214240315100_keae152-B68","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1093\/rheumatology\/keaa757","article-title":"Childhood Sj\u00f6gren syndrome: features of an international cohort and application of the 2016 ACR\/EULAR classification criteria","volume":"60","author":"Basiaga","year":"2021","journal-title":"Rheumatology (Oxford, England)"},{"key":"2025042214240315100_keae152-B69","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12969-022-00779-3","article-title":"Childhood-onset primary Sj\u00f6gren's syndrome in a tertiary center in China: clinical features and outcome","volume":"21","author":"Gong","year":"2023","journal-title":"Pediatr Rheumatol Online J"},{"key":"2025042214240315100_keae152-B70","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1001\/archotol.128.11.1279","article-title":"The role of parotid biopsy in the diagnosis of pediatric Sj\u00f6gren syndrome","volume":"128","author":"McGuirt","year":"2002","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"2025042214240315100_keae152-B71","first-page":"411","article-title":"The role of biopsy in lacrimal gland inflammation: a clinicopathologic study","volume":"36","author":"Luemsamran","year":"2017","journal-title":"Orbit (Amsterdam, Netherlands)"},{"key":"2025042214240315100_keae152-B72","doi-asserted-by":"crossref","first-page":"e3766-e","DOI":"10.1097\/MD.0000000000003766","article-title":"Predicting the risk for lymphoma development in Sjogren syndrome: an easy tool for clinical use","volume":"95","author":"Fragkioudaki","year":"2016","journal-title":"Medicine"},{"key":"2025042214240315100_keae152-B73","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.semarthrit.2011.04.006","article-title":"Risk, predictors, and clinical characteristics of lymphoma development in primary Sjogren's syndrome","volume":"41","author":"Solans-Laque","year":"2011","journal-title":"Semin Arthritis Rheum"},{"key":"2025042214240315100_keae152-B74","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/MD.0b013e3181b76ab5","article-title":"Hematologic manifestations and predictors of lymphoma development in primary Sjogren syndrome: clinical and pathophysiologic aspects","volume":"88","author":"Baimpa","year":"2009","journal-title":"Medicine"},{"key":"2025042214240315100_keae152-B75","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1002\/art.10221","article-title":"Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sj\u00f6gren's syndrome","volume":"46","author":"Ioannidis","year":"2002","journal-title":"Arthritis Rheum"},{"key":"2025042214240315100_keae152-B76","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s13045-017-0464-5","article-title":"Characterization and risk estimate of cancer in patients with primary Sj\u00f6gren syndrome","volume":"10","author":"Brito-Zer\u00f3n","year":"2017","journal-title":"J Hematol Oncol"},{"key":"2025042214240315100_keae152-B77","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1002\/art.39518","article-title":"Rheumatoid factor and disease activity are independent predictors of lymphoma in primary Sj\u00f6gren's syndrome","volume":"68","author":"Nocturne","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2025042214240315100_keae152-B78","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1136\/ard.2010.144782","article-title":"Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sjogren's syndrome","volume":"70","author":"Theander","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2025042214240315100_keae152-B79","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1136\/annrheumdis-2017-211290","article-title":"Germinal centres in diagnostic labial gland biopsies of patients with primary Sj\u00f6gren's syndrome are not predictive for parotid MALT lymphoma development","volume":"76","author":"Haacke","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2025042214240315100_keae152-B80","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1136\/annrheumdis-2013-204634","article-title":"The prognostic value of routinely performed minor salivary gland assessments in primary Sj\u00f6gren's syndrome","volume":"73","author":"Risselada","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2025042214240315100_keae152-B81","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1177\/0961203314554251","article-title":"A retrospective, multicenter study evaluating the prognostic value of minor salivary gland histology in a large cohort of patients with primary Sj\u00f6gren's syndrome","volume":"24","author":"Carubbi","year":"2015","journal-title":"Lupus"},{"key":"2025042214240315100_keae152-B82","doi-asserted-by":"crossref","first-page":"102648","DOI":"10.1016\/j.jaut.2021.102648","article-title":"A biomarker for lymphoma development in Sjogren's syndrome: salivary gland focus score","volume":"121","author":"Chatzis","year":"2021","journal-title":"J Autoimmun"},{"key":"2025042214240315100_keae152-B83","doi-asserted-by":"crossref","first-page":"594096","DOI":"10.3389\/fimmu.2020.594096","article-title":"Primary Sj\u00f6gren\u2019s syndrome of early and late onset: distinct clinical phenotypes and lymphoma development","volume":"11","author":"Goules","year":"2020","journal-title":"Front Immunol"},{"key":"2025042214240315100_keae152-B84","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/MPH.0000000000001321","article-title":"Mucosal-associated Lymphoid Tissue (MALT) Lymphoma in Association With Pediatric Primary Sjogren Syndrome: 2 Cases and Review","volume":"41","author":"Tesher","year":"2019","journal-title":"J Pediatr Hematol\/Oncol"},{"key":"2025042214240315100_keae152-B85","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s10238-021-00728-6","article-title":"Sj\u00f6gren\u2019s syndrome: a systemic autoimmune disease","volume":"22","author":"Negrini","year":"2022","journal-title":"Clin Exp Med"},{"key":"2025042214240315100_keae152-B86","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s10238-021-00772-2","article-title":"Association of immunological features with clinical manifestations in primary Sjogren's syndrome: a single-center cross-sectional study","volume":"22","author":"Relangi","year":"2022","journal-title":"Clin Exp Med"},{"key":"2025042214240315100_keae152-B87","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.rdc.2016.03.002","article-title":"Autoantibodies in Sj\u00f6gren's Syndrome","volume":"42","author":"Fayyaz","year":"2016","journal-title":"Rheum Dis Clin North Am"},{"key":"2025042214240315100_keae152-B88","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s10067-019-04869-8","article-title":"Persistent serological activity in primary Sj\u00f6gren's syndrome","volume":"39","author":"L\u00f3pez-Morales","year":"2020","journal-title":"Clin Rheumatol"},{"key":"2025042214240315100_keae152-B89","first-page":"198","article-title":"Phenotyping Sj\u00f6gren's syndrome: towards a personalised management of the disease","volume":"36(Suppl 112)","author":"Brito-Zer\u00f3n","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"2025042214240315100_keae152-B90","first-page":"78","article-title":"Comorbidity and health care utilisation in persons with Sj\u00f6gren's syndrome: a claims data analysis","volume":"38(Suppl 126)","author":"Albrecht","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"2025042214240315100_keae152-B91","doi-asserted-by":"crossref","first-page":"864448","DOI":"10.3389\/fimmu.2022.864448","article-title":"Comorbidities in the UK Primary Sj\u00f6gren's Syndrome Registry","volume":"13","author":"Tarn","year":"2022","journal-title":"Frontiers in immunology"},{"key":"2025042214240315100_keae152-B92","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1136\/annrheumdis-2021-221733","article-title":"EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome","volume":"81","author":"Drosos","year":"2022","journal-title":"Annals of the Rheumatic Diseases"},{"key":"2025042214240315100_keae152-B93","doi-asserted-by":"crossref","first-page":"12647","DOI":"10.1038\/s41598-022-16705-2","article-title":"Population-based screening for celiac disease reveals that the majority of patients are undiagnosed and improve on a gluten-free diet","volume":"12","author":"Kvamme","year":"2022","journal-title":"Sci Rep"},{"key":"2025042214240315100_keae152-B94","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1007\/s00296-003-0360-x","article-title":"Coeliac disease in Sjogren's syndrome\u2014a study of 111 Hungarian patients","volume":"24","author":"Szodoray","year":"2004","journal-title":"Rheumatol Int"},{"key":"2025042214240315100_keae152-B95","first-page":"2613","article-title":"Autoantibodies to tissue transglutaminase in Sjogren's syndrome and related rheumatic diseases","volume":"30","author":"Luft","year":"2003","journal-title":"J Rheumatol"},{"key":"2025042214240315100_keae152-B96","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1093\/rheumatology\/33.8.745","article-title":"Liver involvement in primary Sjogren's syndrome","volume":"33","author":"Skopouli","year":"1994","journal-title":"Br J Rheumatol"},{"key":"2025042214240315100_keae152-B97","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1093\/rheumatology\/keq240","article-title":"United Kingdom Primary Sjogren's Syndrome Registry\u2014a united effort to tackle an orphan rheumatic disease","volume":"50","author":"Ng","year":"2011","journal-title":"Rheumatology (Oxford, England)"},{"key":"2025042214240315100_keae152-B98","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s10067-012-2005-5","article-title":"Potential diagnostic utility of anti-centromere antibody in primary Sj\u00f6gren\u2019s syndrome in the UK","volume":"31","author":"Collins","year":"2012","journal-title":"Clin Rheumatol"},{"key":"2025042214240315100_keae152-B99","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1053\/jhep.2001.21165","article-title":"Risk factors for primary biliary cirrhosis in a cohort of patients from the united states","volume":"33","author":"Parikh-Patel","year":"2001","journal-title":"Hepatology (Baltimore, Md)"},{"key":"2025042214240315100_keae152-B100","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1136\/ard.60.11.1046","article-title":"Rheumatic disorders and primary biliary cirrhosis: an appraisal of 170 Italian patients","volume":"60","author":"Marasini","year":"2001","journal-title":"Ann Rheum Dis"},{"key":"2025042214240315100_keae152-B101","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1002\/hep.20907","article-title":"Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients","volume":"42","author":"Gershwin","year":"2005","journal-title":"Hepatology (Baltimore, MD)"},{"key":"2025042214240315100_keae152-B102","doi-asserted-by":"crossref","first-page":"5131","DOI":"10.3748\/wjg.v19.i31.5131","article-title":"Connective tissue diseases in primary biliary cirrhosis: a population-based cohort study","volume":"19","author":"Wang","year":"2013","journal-title":"World J Gastroenterol"},{"key":"2025042214240315100_keae152-B103","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/S0168-8278(94)80007-3","article-title":"Autoimmune liver disease in patients with primary Sjogren's syndrome","volume":"20","author":"Lindgren","year":"1994","journal-title":"J Hepatol"},{"key":"2025042214240315100_keae152-B104","first-page":"1593","article-title":"Characterization and differentiation of autoimmune versus viral liver involvement in patients with Sjogren's syndrome","volume":"33","author":"Ramos-Casals","year":"2006","journal-title":"J Rheumatol"},{"key":"2025042214240315100_keae152-B105","first-page":"2012","article-title":"Prevalence and longterm course of primary biliary cirrhosis in primary Sjogren's syndrome","volume":"35","author":"Hatzis","year":"2008","journal-title":"J Rheumatol"},{"key":"2025042214240315100_keae152-B106","first-page":"582","article-title":"Autoimmune hepatitis in patients with primary Sjogren's syndrome: a series of two-hundred and two patients","volume":"3","author":"Karp","year":"2010","journal-title":"Int J Clin Exp pathology"},{"key":"2025042214240315100_keae152-B107","doi-asserted-by":"crossref","first-page":"e014807","DOI":"10.1136\/bmjopen-2016-014807","article-title":"Primary Sjogren's syndrome and the risk of acute pancreatitis: a nationwide cohort study","volume":"7","author":"Chang","year":"2017","journal-title":"BMJ Open"},{"key":"2025042214240315100_keae152-B108","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jaut.2012.01.010","article-title":"Monoclonal gammopathy related to Sj\u00f6gren syndrome: a key marker of disease prognosis and outcomes","volume":"39","author":"Brito-Zer\u00f3n","year":"2012","journal-title":"J Autoimmun"},{"key":"2025042214240315100_keae152-B109","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1093\/mr\/roac066","article-title":"Prevalence and risk factors of monoclonal gammopathy in patients with autoimmune inflammatory rheumatic disease: a systematic review and meta-analysis","volume":"33","author":"Bai","year":"2022","journal-title":"Modern Rheumatol\/Japan Rheum Assoc"},{"key":"2025042214240315100_keae152-B110","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1093\/rheumatology\/keu401","article-title":"Prevalence of distal renal tubular acidosis in primary Sjogren's syndrome","volume":"54","author":"Both","year":"2015","journal-title":"Rheumatology (Oxford, England)"},{"key":"2025042214240315100_keae152-B111","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1093\/rheumatology\/kev223","article-title":"Renal involvement in primary Sjogren's syndrome","volume":"54","author":"Evans","year":"2015","journal-title":"Rheumatology (Oxford, England)"},{"key":"2025042214240315100_keae152-B112","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/sj.ki.5002220","article-title":"Urinary acidification assessed by simultaneous furosemide and fludrocortisone treatment: an alternative to ammonium chloride","volume":"71","author":"Walsh","year":"2007","journal-title":"Kid Int"},{"key":"2025042214240315100_keae152-B113","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12891-015-0858-x","article-title":"Tubulointerstitial nephritis in primary Sjogren syndrome: clinical manifestations and response to treatment","volume":"17","author":"Evans","year":"2016","journal-title":"BMC Musculoskelet Disord"},{"key":"2025042214240315100_keae152-B114","first-page":"343","article-title":"Features of childhood Sjogren's syndrome in comparison to adult Sjogren's syndrome: considerations in establishing child-specific diagnostic criteria","volume":"34","author":"Yokogawa","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"2025042214240315100_keae152-B115","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.autrev.2016.12.006","article-title":"Sjogren's syndrome-associated myositis with germinal centre-like structures","volume":"16","author":"Espitia-Thibault","year":"2017","journal-title":"Autoimmun Rev"},{"key":"2025042214240315100_keae152-B116","first-page":"717","article-title":"Subclinical myositis is common in primary Sjogren's syndrome and is not related to muscle pain","volume":"29","author":"Lindvall","year":"2002","journal-title":"J Rheumatol"},{"key":"2025042214240315100_keae152-B117","first-page":"457","article-title":"Myositis in primary Sjogren's syndrome: data from a multicentre cohort","volume":"33","author":"Colafrancesco","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"2025042214240315100_keae152-B118","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1007\/s00296-012-2556-4","article-title":"Inclusion body myositis associated with Sjogren's syndrome","volume":"33","author":"Misterska-Sk\u00f3ra","year":"2013","journal-title":"Rheumatol Int"},{"key":"2025042214240315100_keae152-B119","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/rheumatology\/41.4.440","article-title":"Primary Sj\u00f6gren's syndrome associated with inclusion body myositis","volume":"41","author":"Kanellopoulos","year":"2002","journal-title":"Rheumatology"},{"key":"2025042214240315100_keae152-B120","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1055\/s-0032-1329197","article-title":"Inclusion body myositis","volume":"32","author":"Dimachkie","year":"2012","journal-title":"Semin Neurol"},{"key":"2025042214240315100_keae152-B121","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1093\/rheumatology\/keaa257","article-title":"Refining myositis associated with primary Sj\u00f6gren\u2019s syndrome: data from the prospective cohort ASSESS","volume":"60","author":"Felten","year":"2020","journal-title":"Rheumatology"},{"key":"2025042214240315100_keae152-B122","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1093\/rheumatology\/keu289","article-title":"Incidence and prevalence of inflammatory myopathies: a systematic review","volume":"54","author":"Meyer","year":"2014","journal-title":"Rheumatology"},{"key":"2025042214240315100_keae152-B123","doi-asserted-by":"crossref","first-page":"947","DOI":"10.3945\/an.117.015578","article-title":"25-Hydroxyvitamin D as a biomarker of vitamin D status and its modeling to inform strategies for prevention of vitamin D deficiency within the population","volume":"8","author":"Cashman","year":"2017","journal-title":"Adv Nutr (Bethesda, MD)"},{"key":"2025042214240315100_keae152-B124","doi-asserted-by":"crossref","first-page":"106","DOI":"10.31138\/mjr.33.1.106","article-title":"Vitamin D Deficiency in Primary Sj\u00f6gren's Syndrome: association with Clinical Manifestations and Immune Activation Markers","volume":"33","author":"Athanassiou","year":"2022","journal-title":"Mediterranean J Rheumatol"},{"key":"2025042214240315100_keae152-B125","doi-asserted-by":"crossref","first-page":"386","DOI":"10.3177\/jnsv.66.386","article-title":"Vitamin D deficiency is associated with severity of dry eye symptoms and primary Sj\u00f6gren's syndrome: a systematic review and meta-analysis","volume":"66","author":"Kuo","year":"2020","journal-title":"J Nutr Sci Vitaminol"},{"key":"2025042214240315100_keae152-B126","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1097\/ICO.0000000000001865","article-title":"Sj\u00f6gren's syndrome: more than just dry eye","volume":"38","author":"Akpek","year":"2019","journal-title":"Cornea"},{"key":"2025042214240315100_keae152-B127","doi-asserted-by":"crossref","first-page":"53","DOI":"10.4103\/ijo.IJO_2383_19","article-title":"Does Sjogren's syndrome affect only the lacrimal gland in the eye? Time to replace the missing stones","volume":"69","author":"Gurlevik","year":"2021","journal-title":"Indian J Ophthalmol"},{"key":"2025042214240315100_keae152-B128","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1159\/000487487","article-title":"Meibomian Gland Dysfunction in Primary and Secondary Sj\u00f6gren Syndrome","volume":"59","author":"Sullivan","year":"2018","journal-title":"Ophthalmic Res"},{"key":"2025042214240315100_keae152-B129","doi-asserted-by":"crossref","first-page":"101865","DOI":"10.1016\/j.clae.2023.101865","article-title":"Symptoms of dry eye related to the relative humidity of living places","volume":"46","author":"Martin","year":"2023","journal-title":"Cont Lens Anterior Eye"},{"key":"2025042214240315100_keae152-B130","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1097\/OPX.0b013e318288bdbe","article-title":"Intrasubject tear osmolarity changes with two different types of eyedrops","volume":"90","author":"Montani","year":"2013","journal-title":"Optom Vis Sci"},{"key":"2025042214240315100_keae152-B131","first-page":"Cd009729","article-title":"Over the counter (OTC) artificial tear drops for dry eye syndrome","volume":"2","author":"Pucker","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"2025042214240315100_keae152-B132","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2147\/OPTO.S350185","article-title":"Artificial tears: a systematic review","volume":"15","author":"Semp","year":"2023","journal-title":"Clin Optom"},{"key":"2025042214240315100_keae152-B133","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.3390\/ijerph18052383","article-title":"A meta-analysis of the efficacy of hyaluronic acid eye drops for the treatment of dry eye syndrome","volume":"18","author":"Yang","year":"2021","journal-title":"Int J Environ Res Public Health"},{"key":"2025042214240315100_keae152-B134","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1111\/aos.14788","article-title":"Allogeneic and autologous serum eye drops: a pilot double-blind randomized crossover trial","volume":"99","author":"van der Meer","year":"2021","journal-title":"Acta Ophthalmol"},{"key":"2025042214240315100_keae152-B135","first-page":"200","article-title":"Serum eye drops for the treatment of ocular surface diseases: a systematic review and meta-analysis","volume":"17","author":"Franchini","year":"2019","journal-title":"Blood Transfusion = Trasfusione del Sangue"},{"key":"2025042214240315100_keae152-B136","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1159\/000505630","article-title":"Autologous serum eye drops versus artificial tear drops for dry eye disease: a systematic review and meta-analysis of randomized controlled trials","volume":"63","author":"Wang","year":"2020","journal-title":"Ophthalmic Res"},{"key":"2025042214240315100_keae152-B137","article-title":"Topical corticosteroids for dry eye","volume":"10","author":"Liu","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"2025042214240315100_keae152-B138","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1089\/jop.2020.0014","article-title":"Loteprednol etabonate for the treatment of dry eye disease","volume":"36","author":"Beckman","year":"2020","journal-title":"J Ocular Pharmacol Ther"},{"key":"2025042214240315100_keae152-B139","doi-asserted-by":"crossref","first-page":"e551","DOI":"10.1097\/MD.0000000000000551","article-title":"Topical fluorometholone treatment for ocular dryness in patients with Sj\u00f6gren syndrome: a randomized clinical trial in China","volume":"94","author":"Lin","year":"2015","journal-title":"Medicine"},{"key":"2025042214240315100_keae152-B140","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.jtos.2019.02.012","article-title":"Efficacy of topical ophthalmic drugs in the treatment of dry eye disease: a systematic literature review","volume":"17","author":"Holland","year":"2019","journal-title":"Ocul Surf"},{"key":"2025042214240315100_keae152-B141","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1399-3038.2006.00427.x","article-title":"Efficacy of 1.25% and 1% topical cyclosporine in the treatment of severe vernal keratoconjunctivitis in childhood","volume":"17","author":"Spadavecchia","year":"2006","journal-title":"Pediatr Allergy Immunol"},{"key":"2025042214240315100_keae152-B142","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13223-021-00513-w","article-title":"Long-term outcomes of 0.1% tacrolimus eye drops in eyes with severe allergic conjunctival diseases","volume":"17","author":"Yazu","year":"2021","journal-title":"Allergy Asthma Clin Immunol"},{"key":"2025042214240315100_keae152-B143","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1097\/ICO.0b013e31823f8c9b","article-title":"Clinical treatment of dry eye using 0.03% tacrolimus eye drops","volume":"31","author":"Moscovici","year":"2012","journal-title":"Cornea"},{"key":"2025042214240315100_keae152-B144","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1177\/1120672121992680","article-title":"Evaluation of the effect of topical tacrolimus 0.03% versus cyclosporine 0.05% in the treatment of dry eye secondary to Sjogren syndrome","volume":"32","author":"Moawad","year":"2022","journal-title":"Eur J Ophthalmol"},{"key":"2025042214240315100_keae152-B145","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1001\/jamaophthalmol.2013.195","article-title":"Topical interleukin 1 receptor antagonist for treatment of dry eye disease: a randomized clinical trial","volume":"131","author":"Amparo","year":"2013","journal-title":"JAMA Ophthalmol"},{"key":"2025042214240315100_keae152-B146","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.2147\/OPTH.S40798","article-title":"Rebamipide ophthalmic suspension for the treatment of dry eye syndrome: a critical appraisal","volume":"8","author":"Kashima","year":"2014","journal-title":"Clin Ophthalmol"},{"key":"2025042214240315100_keae152-B147","doi-asserted-by":"crossref","first-page":"207","DOI":"10.4103\/ojo.OJO_29_2017","article-title":"Efficacy of rebamipide 2% ophthalmic solution in the treatment of dry eyes","volume":"11","author":"Shrivastava","year":"2018","journal-title":"Oman J Ophthalmol"},{"key":"2025042214240315100_keae152-B148","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1159\/000492896","article-title":"Efficacy and safety of topical 3% diquafosol ophthalmic solution for the treatment of multifactorial dry eye disease: meta-analysis of randomized clinical trials","volume":"61","author":"Nam","year":"2019","journal-title":"Ophthalmic Res"},{"key":"2025042214240315100_keae152-B149","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1080\/14397595.2020.1816319","article-title":"Clinical practice guidance for Sj\u00f6gren's syndrome in pediatric patients (2018) - summarized and updated","volume":"31","author":"Tomiita","year":"2021","journal-title":"Modern Rheumatol\/Japan Rheum Assoc"},{"key":"2025042214240315100_keae152-B150","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/ICL.0000000000000680","article-title":"A review on evidence-based treatments for meibomian gland dysfunction","volume":"46","author":"Lam","year":"2020","journal-title":"Eye Contact Lens"},{"key":"2025042214240315100_keae152-B151","first-page":"CD013559","article-title":"Intense pulsed light (IPL) therapy for the treatment of meibomian gland dysfunction","volume":"3","author":"Cote","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"2025042214240315100_keae152-B152","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00417-020-04834-1","article-title":"Intense pulsed light for meibomian gland dysfunction: a systematic review and meta-analysis","volume":"259","author":"Leng","year":"2021","journal-title":"Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie"},{"key":"2025042214240315100_keae152-B153","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1097\/ICO.0b013e3181d836f3","article-title":"Intraductal meibomian gland probing relieves symptoms of obstructive meibomian gland dysfunction","volume":"29","author":"Maskin","year":"2010","journal-title":"Cornea"},{"key":"2025042214240315100_keae152-B154","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.jtos.2022.08.010","article-title":"Antibiotic treatment for dry eye disease related to meibomian gland dysfunction and blepharitis\u2014a review","volume":"26","author":"Vernhardsdottir","year":"2022","journal-title":"Ocul Surf"},{"key":"2025042214240315100_keae152-B155","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1097\/OPX.0b013e31826f32e0","article-title":"Lipid-containing lubricants for dry eye: a systematic review","volume":"89","author":"Lee","year":"2012","journal-title":"Optometry Vis Sci"},{"key":"2025042214240315100_keae152-B156","first-page":"Cd006775","article-title":"Punctal occlusion for dry eye syndrome","volume":"6","author":"Ervin","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"2025042214240315100_keae152-B157","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1507\/endocrj.EJ20-0178","article-title":"The applications of androgen in the treatment of dry eye disease: a systematic review of clinical studies","volume":"67","author":"Wang","year":"2020","journal-title":"Endocrine J"},{"key":"2025042214240315100_keae152-B158","first-page":"CD008934","article-title":"Interventions for the management of dry mouth: topical therapies","volume":"12","author":"Furness","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"2025042214240315100_keae152-B159","first-page":"CD009603","article-title":"Interventions for the management of dry mouth: non-pharmacological interventions","volume":"2013","author":"Furness","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"2025042214240315100_keae152-B160","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/odi.13752","article-title":"Oil pulling to relieve medication-induced xerostomia: a randomized, single-blind, crossover trial","volume":"28","author":"Ludwar","year":"2022","journal-title":"Oral Dis"},{"key":"2025042214240315100_keae152-B161","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1080\/03009740510017959","article-title":"Reproduction and gynaecological manifestations in women with primary Sjogren's syndrome: a case-control study","volume":"34","author":"Haga","year":"2005","journal-title":"Scand J Rheumatol"},{"key":"2025042214240315100_keae152-B162","article-title":"Local oestrogen for vaginal atrophy in postmenopausal women","volume":"2016","author":"Lethaby","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"2025042214240315100_keae152-B163","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1097\/GME.0000000000001284","article-title":"Vaginal estrogen use and chronic disease risk in the Nurses' Health Study","volume":"26","author":"Bhupathiraju","year":"2018","journal-title":"Menopause (New York, NY)"},{"key":"2025042214240315100_keae152-B164","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1111\/jsm.12125","article-title":"Evaluation of the efficacy and safety of hyaluronic acid vaginal gel to ease vaginal dryness: a multicenter, randomized, controlled, open-label, parallel-group, clinical trial","volume":"10","author":"Chen","year":"2013","journal-title":"J Sex Med"},{"key":"2025042214240315100_keae152-B165","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1007\/s00404-013-3068-5","article-title":"Is vaginal hyaluronic acid as effective as vaginal estriol for vaginal dryness relief?","volume":"288","author":"Stute","year":"2013","journal-title":"Arch Gynecol Obstet"},{"key":"2025042214240315100_keae152-B166","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/S1701-2163(16)30662-4","article-title":"The detection and management of vaginal atrophy","volume":"26","author":"Johnston","year":"2004","journal-title":"J Obstet Gynaecol Can"},{"key":"2025042214240315100_keae152-B167","doi-asserted-by":"crossref","first-page":"387","DOI":"10.2147\/IJWH.S158913","article-title":"Current treatment options for postmenopausal vaginal atrophy","volume":"10","author":"Naumova","year":"2018","journal-title":"Int J Women's Health"},{"key":"2025042214240315100_keae152-B168","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1136\/ard.2002.003889","article-title":"Oral pilocarpine for the treatment of ocular symptoms in patients with Sjogren's syndrome: a randomised 12 week controlled study","volume":"62","author":"Tsifetaki","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"2025042214240315100_keae152-B169","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1001\/archinte.159.2.174","article-title":"Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sj\u00f6gren syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial. P92-01 Study Group","volume":"159","author":"Vivino","year":"1999","journal-title":"Arch Intern Med"},{"key":"2025042214240315100_keae152-B170","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/art.510","article-title":"A double-blind, randomized, placebo-controlled study of cevimeline in Sjogren's syndrome patients with xerostomia and keratoconjunctivitis sicca","volume":"46","author":"Petrone","year":"2002","journal-title":"Arthritis Rheum"},{"key":"2025042214240315100_keae152-B171","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ajo.2004.02.010","article-title":"Therapeutic effect of cevimeline on dry eye in patients with Sj\u00f6gren's syndrome: a randomized, double-blind clinical study","volume":"138","author":"Ono","year":"2004","journal-title":"Am J Ophthalmol"},{"key":"2025042214240315100_keae152-B172","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/01.rhu.0000135553.08057.21","article-title":"Successful treatment of dry mouth and dry eye symptoms in Sj\u00f6gren's syndrome patients with oral pilocarpine: a randomized, placebo-controlled, dose-adjustment study","volume":"10","author":"Papas","year":"2004","journal-title":"J Clin Rheumatol"},{"key":"2025042214240315100_keae152-B173","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1001\/archinte.162.11.1293","article-title":"Cevimeline for the treatment of xerostomia in patients with Sjogren syndrome: a randomized trial","volume":"162","author":"Fife","year":"2002","journal-title":"Arch Intern Med"},{"key":"2025042214240315100_keae152-B174","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s10067-007-0723-x","article-title":"The efficacy of cevimeline hydrochloride in the treatment of xerostomia in Sj\u00f6gren\u2019s syndrome in southern Chinese patients: a randomised double-blind, placebo-controlled crossover study","volume":"27","author":"Leung","year":"2008","journal-title":"Clin Rheumatol"},{"key":"2025042214240315100_keae152-B175","first-page":"575","article-title":"Comparison of the discontinuation rates and side-effect profiles of pilocarpine and cevimeline for xerostomia in primary Sjogren's syndrome","volume":"32","author":"Noaiseh","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"2025042214240315100_keae152-B176","volume":"1","author":"Walsh","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"2025042214240315100_keae152-B177","author":"Public Health England. Delivering better oral health: An evidence-based toolkit for prevention. London: Public Health England"},{"key":"2025042214240315100_keae152-B178","first-page":"CD010743","article-title":"Xylitol-containing products for preventing dental caries in children and adults","volume":"2015","author":"Riley","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"2025042214240315100_keae152-B179","article-title":"Chlorhexidine treatment for the prevention of dental caries in children and adolescents","volume":"2015","author":"Walsh","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"2025042214240315100_keae152-B180","article-title":"Water fluoridation for the prevention of dental caries","volume":"2015","author":"Iheozor-Ejiofor","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"2025042214240315100_keae152-B181","article-title":"Fluoride varnishes for preventing dental caries in children and adolescents","volume":"2013","author":"Marinho","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"2025042214240315100_keae152-B182","article-title":"Home use of interdental cleaning devices, in addition to toothbrushing, for preventing and controlling periodontal diseases and dental caries","volume":"2020","author":"Worthington","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"2025042214240315100_keae152-B183","doi-asserted-by":"crossref","DOI":"10.1016\/j.adaj.2015.11.008","article-title":"Clinical practice guidelines for oral management of Sj\u00f6gren disease: dental caries prevention","author":"Zero","year":"2016","journal-title":"J Am Dent Assoc"},{"key":"2025042214240315100_keae152-B184","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1093\/rheumatology\/ket427","article-title":"Primary Sjogren's syndrome as a multi-organ disease: impact of the serological profile on the clinical presentation of the disease in a large cohort of Italian patients","volume":"53","author":"Baldini","year":"2014","journal-title":"Rheumatology (Oxford, England)"},{"key":"2025042214240315100_keae152-B185","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.1093\/rheumatology\/key363","article-title":"How to treat Sj\u00f6gren's syndrome","volume":"60","author":"Price","year":"2021","journal-title":"Rheumatology (Oxford, England)"},{"key":"2025042214240315100_keae152-B186","article-title":"Prevalence and identification of neuropsychiatric symptoms in systemic autoimmune rheumatic diseases: an international mixed methods study","author":"Sloan","year":"2023","journal-title":"Rheumatology"},{"key":"2025042214240315100_keae152-B187","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1093\/rheumatology\/kep104","article-title":"Treatment of sicca symptoms with hydroxychloroquine in patients with Sjogren's syndrome","volume":"48","author":"Rihl","year":"2009","journal-title":"Rheumatology (Oxford, England)"},{"key":"2025042214240315100_keae152-B188","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1177\/0961203396005001081","article-title":"Treatment of primary Sjogren's syndrome with hydroxychloroquine: a retrospective, open-label study","volume":"5","author":"Fox","year":"1996","journal-title":"Lupus"},{"key":"2025042214240315100_keae152-B189","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1136\/ard.52.5.360","article-title":"Hydroxychloroquine treatment for primary Sjogren's syndrome: a two year double blind crossover trial","volume":"52","author":"Kruize","year":"1993","journal-title":"Ann Rheum Dis"},{"key":"2025042214240315100_keae152-B190","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1136\/ard.58.4.253","article-title":"Hydroxychloroquine treatment for primary Sjogren's syndrome: its effect on salivary and serum inflammatory markers","volume":"58","author":"Tishler","year":"1999","journal-title":"Ann Rheum Dis"},{"key":"2025042214240315100_keae152-B191","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/jama.2014.7682","article-title":"Effects of hydroxychloroquine on symptomatic improvement in primary Sjogren syndrome: the JOQUER randomized clinical trial","volume":"312","author":"Gottenberg","year":"2014","journal-title":"Jama"},{"key":"2025042214240315100_keae152-B192","volume-title":"Antimalarials for Sjogren's syndrome treatment in adults, meta-analysis. Arthritis and rheumatism","author":"Coy","year":"2012"},{"key":"2025042214240315100_keae152-B193","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1007\/s00296-010-1415-4","article-title":"Hydroxychloroquine improves dry eye symptoms of patients with primary Sjogren's syndrome","volume":"31","author":"Yavuz","year":"2011","journal-title":"Rheumatol Int"},{"key":"2025042214240315100_keae152-B194","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.3346\/jkms.2016.31.7.1127","article-title":"Effect of hydroxychloroquine treatment on dry eyes in subjects with primary sjogren's syndrome: a double-blind randomized control study","volume":"31","author":"Yoon","year":"2016","journal-title":"J Korean Med Sci"},{"key":"2025042214240315100_keae152-B195","doi-asserted-by":"crossref","first-page":"e85","DOI":"10.1016\/S2665-9913(19)30042-6","article-title":"Symptom-based stratification of patients with primary Sj\u00f6gren's syndrome: multi-dimensional characterisation of international observational cohorts and reanalyses of randomised clinical trials","volume":"1","author":"Tarn","year":"2019","journal-title":"Lancet Rheumatol"},{"key":"2025042214240315100_keae152-B196","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1007\/s00296-021-04927-y","article-title":"Revisiting the JOQUER trial: stratification of primary Sj\u00f6gren's syndrome and the clinical and interferon response to hydroxychloroquine","volume":"41","author":"Collins","year":"2021","journal-title":"Rheumatol Int"},{"key":"2025042214240315100_keae152-B197","doi-asserted-by":"crossref","first-page":"693796","DOI":"10.3389\/fphar.2021.693796","article-title":"The efficiency of hydroxychloroquine for the treatment of primary Sj\u00f6gren's syndrome: a systematic review and meta-analysis","volume":"12","author":"Wang","year":"2021","journal-title":"Front Pharmacol"},{"key":"2025042214240315100_keae152-B198","doi-asserted-by":"crossref","first-page":"114","DOI":"10.55563\/clinexprheumatol\/volsh1","article-title":"Hypergammaglobulinaemia predicts glandular and extra-glandular damage in primary Sj\u00f6gren's syndrome: results from the KISS cohort study","volume":"39(Suppl 133)","author":"Koh","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"2025042214240315100_keae152-B199","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1007\/s10067-017-3822-3","article-title":"Primary Sjogren's syndrome: extraglandular manifestations and hydroxychloroquine therapy","volume":"36","author":"Demarchi","year":"2017","journal-title":"Clin Rheumatol"},{"key":"2025042214240315100_keae152-B200","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.reuma.2015.09.003","article-title":"Sjogren's syndrome-associated interstitial lung disease: a multicenter study","volume":"12","author":"Reina","year":"2016","journal-title":"Reumatol Clin"},{"key":"2025042214240315100_keae152-B201","doi-asserted-by":"crossref","first-page":"e73774","DOI":"10.1371\/journal.pone.0073774","article-title":"Prognostic factors in interstitial lung disease associated with primary Sjogren's syndrome: a retrospective analysis of 33 pathologically-proven cases","volume":"8","author":"Enomoto","year":"2013","journal-title":"PLoS One"},{"key":"2025042214240315100_keae152-B202","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.autrev.2016.09.017","article-title":"Interstitial lung disease in primary Sjogren's syndrome","volume":"16","author":"Roca","year":"2016","journal-title":"Autoimmun Rev"},{"key":"2025042214240315100_keae152-B203","first-page":"1539","article-title":"Successful treatment with prednisolone for autoimmune myelofibrosis accompanied with Sjogren syndrome]","volume":"48","author":"Hattori","year":"2007","journal-title":"Rinsho Ketsueki"},{"key":"2025042214240315100_keae152-B204","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1001\/archneur.58.5.815","article-title":"Treatment of myelopathy in Sjogren syndrome with a combination of prednisone and cyclophosphamide","volume":"58","author":"Williams","year":"2001","journal-title":"Arch Neurol"},{"key":"2025042214240315100_keae152-B205","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1212\/WNL.52.2.386","article-title":"Improvement of myelopathy in Sjogren's syndrome with chlorambucil and prednisone therapy","volume":"52","author":"Wright","year":"1999","journal-title":"Neurology"},{"key":"2025042214240315100_keae152-B206","doi-asserted-by":"crossref","first-page":"938","DOI":"10.2169\/internalmedicine.38.938","article-title":"Efficacy of low-dose prednisolone maintenance for saliva production and serological abnormalities in patients with primary Sjogren's syndrome","volume":"38","author":"Miyawaki","year":"1999","journal-title":"Intern Med (Tokyo, Japan)"},{"key":"2025042214240315100_keae152-B207","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/acr.22968","article-title":"Treatment guidelines for rheumatologic manifestations of Sjogren's: use of biologics, management of fatigue and inflammatory musculoskeletal pain","volume":"69","author":"Carsons","year":"2016","journal-title":"Arthritis Care Res"},{"key":"2025042214240315100_keae152-B208","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.rdc.2016.03.010","article-title":"New Treatment Guidelines for Sjogren's Disease","volume":"42","author":"Vivino","year":"2016","journal-title":"Rheum Dis Clin North Am"},{"key":"2025042214240315100_keae152-B209","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1093\/rheumatology\/keab579","article-title":"Treatment strategies for Sj\u00f6gren\u2019s syndrome with childhood onset: a systematic review of the literature","volume":"61","author":"Doolan","year":"2021","journal-title":"Rheumatology"},{"key":"2025042214240315100_keae152-B210","first-page":"896","article-title":"A double blind placebo controlled trial of azathioprine in the treatment of primary Sjogren's syndrome","volume":"25","author":"Price","year":"1998","journal-title":"J Rheumatol"},{"key":"2025042214240315100_keae152-B211","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1001\/archneur.59.5.875","article-title":"Treatment of Sjogren syndrome myelopathy with azathioprine and steroids","volume":"59","author":"Hawley","year":"2002","journal-title":"Arch Neurol"},{"key":"2025042214240315100_keae152-B212","first-page":"555","article-title":"Methotrexate in primary Sjogren's syndrome","volume":"14","author":"Skopouli","year":"1996","journal-title":"Clin Exp Rheumatol"},{"key":"2025042214240315100_keae152-B213","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1136\/ard.2006.060905","article-title":"Safety and efficacy of leflunomide in primary Sjogren's syndrome: a phase II pilot study","volume":"66","author":"van Woerkom","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"2025042214240315100_keae152-B214","doi-asserted-by":"crossref","first-page":"R115","DOI":"10.1186\/ar2322","article-title":"Mycophenolate sodium treatment in patients with primary Sjogren syndrome: a pilot trial","volume":"9","author":"Willeke","year":"2007","journal-title":"Arthritis Res Ther"},{"key":"2025042214240315100_keae152-B215","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S0012-3692(15)50949-5","article-title":"Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease","volume":"130","author":"Swigris","year":"2006","journal-title":"Chest"},{"key":"2025042214240315100_keae152-B216"},{"key":"2025042214240315100_keae152-B217","doi-asserted-by":"crossref","first-page":"637","DOI":"10.3109\/s10165-011-0440-9","article-title":"Long-term remission of pulmonary veno-occlusive disease associated with primary Sjogren's syndrome following immunosuppressive therapy","volume":"21","author":"Naniwa","year":"2011","journal-title":"Modern Rheumatol\/Japan Rheum Assoc"},{"key":"2025042214240315100_keae152-B218","first-page":"482","article-title":"Autoimmune hemolytic anemia preceding Sjogren's syndrome","volume":"10","author":"Schattner","year":"1983","journal-title":"J Rheumatol"},{"key":"2025042214240315100_keae152-B219","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1080\/14397595.2018.1438093","article-title":"Clinical practice guideline for Sjogren's syndrome 2017","volume":"28","author":"Sumida","year":"2018","journal-title":"Modern Rheumatol\/Japan Rheum Assoc"},{"key":"2025042214240315100_keae152-B220","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1093\/rheumatology\/keh554","article-title":"BSR guidelines on standards of care for persons with rheumatoid arthritis","volume":"44","author":"Kennedy","year":"2005","journal-title":"Rheumatology (Oxford, England)"},{"key":"2025042214240315100_keae152-B221","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1038\/nrrheum.2016.100","article-title":"Treatment of primary Sj\u00f6gren syndrome","volume":"12","author":"Saraux","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"2025042214240315100_keae152-B222","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1590\/S0482-50042012000200013","article-title":"Mycophenolate mofetil in primary Sjogren's syndrome: a treatment option for agranulocytosis","volume":"52","author":"Fialho","year":"2012","journal-title":"Rev Brasil Reumatol"},{"key":"2025042214240315100_keae152-B223","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/BOR.0000000000000270","article-title":"Management of connective tissue diseases associated interstitial lung disease: a review of the published literature","volume":"28","author":"Wallace","year":"2016","journal-title":"Curr Opin Rheumatol"},{"key":"2025042214240315100_keae152-B224","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1007\/s00296-016-3463-x","article-title":"Dramatic improvement of anti-SS-A\/Ro-associated interstitial lung disease after immunosuppressive treatment","volume":"36","author":"Paola","year":"2016","journal-title":"Rheumatol Int"},{"key":"2025042214240315100_keae152-B225","doi-asserted-by":"crossref","first-page":"640","DOI":"10.3899\/jrheum.121043","article-title":"Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease","volume":"40","author":"Fischer","year":"2013","journal-title":"J Rheumatol"},{"key":"2025042214240315100_keae152-B226","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1080\/1744666X.2019.1624527","article-title":"Additive immunosuppressive effect of leflunomide and hydroxychloroquine supports rationale for combination therapy for Sj\u00f6gren\u2019s syndrome","volume":"15","author":"van der Heijden","year":"2019","journal-title":"Expert Rev Clin Immunol"},{"key":"2025042214240315100_keae152-B227","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jbspin.2014.12.007","article-title":"Sjogren's syndrome complicated by interstitial cystitis: a case series and literature review","volume":"82","author":"Darrieutort-Laffite","year":"2015","journal-title":"Joint Bone Spine"},{"key":"2025042214240315100_keae152-B228","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/1346-8138.12475","article-title":"Annular erythema of Sjogren's syndrome treated successfully with low-dose cyclosporine","volume":"41","author":"Nobeyama","year":"2014","journal-title":"J Dermatol"},{"key":"2025042214240315100_keae152-B229","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1007\/s00296-010-1782-x","article-title":"Interstitial cystitis: a rare manifestation of primary Sjogren's syndrome, successfully treated with low dose cyclosporine","volume":"32","author":"Emmungil","year":"2012","journal-title":"Rheumatol Int"},{"key":"2025042214240315100_keae152-B230","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3109\/s10165-003-0242-9","article-title":"Successful treatment of pure red cell aplasia and autoimmune cytopenia with cyclosporine and prednisolone in a patient with Sjogren's syndrome","volume":"13","author":"Shiratsuchi","year":"2003","journal-title":"Mod Rheumatol"},{"key":"2025042214240315100_keae152-B231","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1007\/BF01452266","article-title":"Very low-dose cyclosporin treatment of steroid-resistant interstitial pneumonitis associated with Sjogren's syndrome","volume":"17","author":"Ogasawara","year":"1998","journal-title":"Clin Rheumatol"},{"key":"2025042214240315100_keae152-B232","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1136\/annrheumdis-2015-eular.2806","article-title":"THU0399 effectiveness and safety of low-dose cyclosporine a in patients with primary Sj\u00f6gren's Syndrome (PSS) with articular involvement\u2013results of a pilot study","volume":"74","author":"Kedor","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2025042214240315100_keae152-B233","first-page":"709","article-title":"Myelopathies secondary to Sjogren's syndrome: treatment with monthly intravenous cyclophosphamide associated with corticosteroids","volume":"33","author":"de Seze","year":"2006","journal-title":"J Rheumatol"},{"key":"2025042214240315100_keae152-B234","doi-asserted-by":"crossref","first-page":"934","DOI":"10.5114\/aoms.2012.30788","article-title":"Cyclophosphamide-rescued plasmapheresis-unresponsive secondary thrombotic thrombocytopenic purpura caused by Sjogren's syndrome","volume":"8","author":"Lin","year":"2012","journal-title":"Arch Med Sci"},{"key":"2025042214240315100_keae152-B235","doi-asserted-by":"crossref","first-page":"171","DOI":"10.5414\/CN107283","article-title":"Type III membranoproliferative glomerulonephritis in a patient with primary Sjogren's syndrome","volume":"79","author":"Sun","year":"2013","journal-title":"Clin Nephrol"},{"key":"2025042214240315100_keae152-B236","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1080\/03009740701867323","article-title":"Sjogren's syndrome\u2014not just Sicca: renal involvement in Sjogren's syndrome","volume":"37","author":"Kaufman","year":"2008","journal-title":"Scand J Rheumatol"},{"key":"2025042214240315100_keae152-B237","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/1529-0131(199807)41:7<1215::AID-ART11>3.0.CO;2-Y","article-title":"Intravenous pulse cyclophosphamide in the treatment of interstitial lung disease due to collagen vascular diseases","volume":"41","author":"Schnabel","year":"1998","journal-title":"Arthritis Rheum"},{"key":"2025042214240315100_keae152-B238","doi-asserted-by":"crossref","first-page":"e553","DOI":"10.1016\/S2665-9913(21)00122-3","article-title":"Composite of Relevant Endpoints for Sj\u00f6gren's Syndrome (CRESS): development and validation of a novel outcome measure","volume":"3","author":"Arends","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"2025042214240315100_keae152-B239","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1136\/annrheumdis-2021-222054","article-title":"Development and preliminary validation of the Sj\u00f6gren\u2019s Tool for Assessing Response (STAR): a consensual composite score for assessing treatment effect in primary Sj\u00f6gren\u2019s syndrome","volume":"81","author":"Seror","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2025042214240315100_keae152-B240","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1002\/acr.22052","article-title":"Evaluation of histologic, serologic, and clinical changes in response to abatacept treatment of primary Sjogren's syndrome: a pilot study","volume":"65","author":"Adler","year":"2013","journal-title":"Arthritis Care Res"},{"key":"2025042214240315100_keae152-B241","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1136\/annrheumdis-2013-204653","article-title":"Abatacept treatment reduces disease activity in early primary Sjogren's syndrome (open-label proof of concept ASAP study)","volume":"73","author":"Meiners","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2025042214240315100_keae152-B242","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s10067-019-04724-w","article-title":"Effectiveness and safety of abatacept for the treatment of patients with primary Sjogren's syndrome","volume":"39","author":"Machado","year":"2020","journal-title":"Clin Rheumatol"},{"key":"2025042214240315100_keae152-B243","doi-asserted-by":"crossref","first-page":"e153","DOI":"10.1016\/S2665-9913(19)30160-2","article-title":"Abatacept treatment for patients with early active primary Sj\u00f6gren's syndrome: a single-centre, randomised, double-blind, placebo-controlled, phase 3 trial (ASAP-III study)","volume":"2","author":"van Nimwegen","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"2025042214240315100_keae152-B244","doi-asserted-by":"crossref","first-page":"e30123","DOI":"10.1371\/journal.pone.0030123","article-title":"Interleukin-1 inhibition and fatigue in primary Sjogren's syndrome\u2014a double blind, randomised clinical trial","volume":"7","author":"Norheim","year":"2012","journal-title":"PLoS One"},{"key":"2025042214240315100_keae152-B245","doi-asserted-by":"crossref","first-page":"888392","DOI":"10.3389\/fimmu.2022.888392","article-title":"Systematic review of safety and efficacy of IL-1-targeted biologics in treating immune-mediated disorders","volume":"13","author":"Arnold","year":"2022","journal-title":"Front Immunol"},{"key":"2025042214240315100_keae152-B246","doi-asserted-by":"crossref","first-page":"3301","DOI":"10.1002\/art.10674","article-title":"Infliximab in primary Sjogren's syndrome: one-year followup","volume":"46","author":"Steinfeld","year":"2002","journal-title":"Arthritis Rheum"},{"key":"2025042214240315100_keae152-B247","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1002\/1529-0131(200110)44:10<2371::AID-ART401>3.0.CO;2-W","article-title":"Infliximab in patients with primary Sjogren's syndrome: a pilot study","volume":"44","author":"Steinfeld","year":"2001","journal-title":"Arthritis Rheum"},{"key":"2025042214240315100_keae152-B248","first-page":"814","article-title":"Notice of retraction of two articles (\u201cInfliximab in patients with primary Sjogren's syndrome: a pilot study\u201d and \u201cInfliximab in patients with primary Sjogren's syndrome: one-year followup","volume":"65","author":"Steinfeld","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2025042214240315100_keae152-B249","first-page":"96","article-title":"Etanercept in the treatment of patients with primary Sjogren's syndrome: a pilot study","volume":"31","author":"Zandbelt","year":"2004","journal-title":"J Rheumatol"},{"key":"2025042214240315100_keae152-B250","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1002\/art.20299","article-title":"Etanercept in Sjogren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial","volume":"50","author":"Sankar","year":"2004","journal-title":"Arthritis Rheum"},{"key":"2025042214240315100_keae152-B251","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/art.20146","article-title":"Inefficacy of infliximab in primary Sjogren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjogren's Syndrome (TRIPSS)","volume":"50","author":"Mariette","year":"2004","journal-title":"Arthritis Rheum"},{"key":"2025042214240315100_keae152-B252","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1002\/art.40513","article-title":"Clinical efficacy and safety of baminercept, a lymphotoxin \u03b2 receptor fusion protein, in primary Sj\u00f6gren's syndrome: results from a phase II randomized, double-blind, placebo-controlled trial","volume":"70","author":"St Clair","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"2025042214240315100_keae152-B253","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1136\/annrheumdis-2013-203991","article-title":"Efficacy and safety of belimumab in primary Sjogren's syndrome: results of the BELISS open-label phase II study","volume":"74","author":"Mariette","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2025042214240315100_keae152-B254","first-page":"199","article-title":"Double anti-B cell and anti-BAFF targeting for the treatment of primary Sjogren's syndrome","volume":"37(Suppl 118)","author":"Gandolfo","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"2025042214240315100_keae152-B255","first-page":"490","article-title":"Sequential therapy with belimumab followed by rituximab in Sjogren's syndrome associated with B-cell lymphoproliferation and overexpression of BAFF: evidence for long-term efficacy","volume":"32","author":"De Vita","year":"2014","journal-title":"Clin Exp rheumatology"},{"key":"2025042214240315100_keae152-B256","doi-asserted-by":"crossref","first-page":"78.2","DOI":"10.1136\/annrheumdis-2021-eular.2170","article-title":"OP0135 safety and efficacy of subcutaneous belimumab and intravenous rituximab combination in patients with primary Sj\u00f6gren\u2019s syndrome: a phase 2, randomised, placebo-controlled 68-week study","volume":"80","author":"Mariette","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2025042214240315100_keae152-B257","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2019-216114","article-title":"EULAR recommendations for the management of Sj\u00f6gren\u2019s syndrome with topical and systemic therapies","volume":"79","author":"Ramos-Casals","year":"2020","journal-title":"Annals of the Rheumatic Diseases"},{"key":"2025042214240315100_keae152-B258","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s12969-022-00740-4","article-title":"Pediatric rheumatologists' perspectives on diagnosis, treatment, and outcomes of Sj\u00f6gren disease in children and adolescents","volume":"20","author":"Randell","year":"2022","journal-title":"Pediatric rheumatology online journal"},{"key":"2025042214240315100_keae152-B259","doi-asserted-by":"crossref","first-page":"R129","DOI":"10.1186\/ar2018","article-title":"Epratuzumab (humanised anti-CD22 antibody) in primary Sjogren's syndrome: an open-label phase I\/II study","volume":"8","author":"Steinfeld","year":"2006","journal-title":"Arthritis research & therapy"},{"key":"2025042214240315100_keae152-B260","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/art.39856","article-title":"Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials","volume":"69","author":"Clowse","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2025042214240315100_keae152-B261","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/art.40425","article-title":"Efficacy of Epratuzumab, an Anti-CD22 Monoclonal IgG Antibody, in Systemic Lupus Erythematosus Patients With Associated Sjogren's Syndrome: post Hoc Analyses From the EMBODY Trials","volume":"70","author":"Gottenberg","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"2025042214240315100_keae152-B262","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1136\/annrheumdis-2018-214720","article-title":"Treatment of primary Sjogren's syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity","volume":"78","author":"Dorner","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2025042214240315100_keae152-B263","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1136\/annrheumdis-2020-eular.364","volume":"79","author":"D\u00f6rner","journal-title":"Ann Rheum Dis"},{"key":"2025042214240315100_keae152-B264","doi-asserted-by":"crossref","first-page":"e142","DOI":"10.1016\/S2665-9913(19)30135-3","article-title":"Assessment of the anti-CD40 antibody iscalimab in patients with primary Sj\u00f6gren's syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study","volume":"2","author":"Fisher","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"2025042214240315100_keae152-B265","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1002\/art.40589","article-title":"JAK-1 inhibition suppresses interferon-induced BAFF production in human salivary gland: potential therapeutic strategy for primary Sjogren\u2019s syndrome","volume":"70","author":"Lee","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"2025042214240315100_keae152-B266","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s12272-019-01124-1","article-title":"Development of BTK inhibitors for the treatment of B-cell malignancies","volume":"42","author":"Kim","year":"2019","journal-title":"Arch Pharm Res"},{"key":"2025042214240315100_keae152-B267","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.4049\/jimmunol.1800583","article-title":"Efficacy and pharmacodynamic modeling of the BTK inhibitor evobrutinib in autoimmune disease models","volume":"202","author":"Haselmayer","year":"2019","journal-title":"J Immunol (Baltimore, MD: 1950)"},{"key":"2025042214240315100_keae152-B268","author":"Cenni"},{"key":"2025042214240315100_keae152-B269","author":"D\u00f6rner"},{"key":"2025042214240315100_keae152-B270","article-title":"A phase 2a study of MEDI5872 (AMG557). A fully human anti-ICOS ligand monoclonal antibody in patients with primary Sj\u00f6gren\u2019s syndrome [abstract]","volume":"71(Suppl 10","author":"Mariette","year":"2019","journal-title":". Arthritis Rheumatol"},{"key":"2025042214240315100_keae152-B271","doi-asserted-by":"crossref","first-page":"3644","DOI":"10.1093\/rheumatology\/kead092","article-title":"A randomized, double-blind, placebo-controlled, parallel group study on the effects of a cathepsin S inhibitor in primary Sj\u00f6gren's syndrome","volume":"62","author":"Bentley","year":"2023","journal-title":"Rheumatology (Oxford, England)"},{"key":"2025042214240315100_keae152-B272","doi-asserted-by":"crossref","first-page":"111","DOI":"10.7863\/jum.2010.29.1.111","article-title":"The tortoiseshell pattern in one or both sides of the submandibular glands in mucosa-associated lymphoid tissue lymphoma is related to chromosomal aberrations and the disease extent","volume":"29","author":"Asai","year":"2010","journal-title":"J Ultrasound Med"},{"key":"2025042214240315100_keae152-B273","doi-asserted-by":"crossref","first-page":"e16285","DOI":"10.1097\/MD.0000000000016285","article-title":"Refractory Sjogren's syndrome myelopathy successfully treated with subcutaneous tocilizumab: a case report","volume":"98","author":"Ishikawa","year":"2019","journal-title":"Medicine"},{"key":"2025042214240315100_keae152-B274","first-page":"329","volume":"80","author":"Felten"},{"key":"2025042214240315100_keae152-B275","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1002\/art.21260","article-title":"Rituximab treatment in patients with primary Sjogren's syndrome: an open-label phase II study","volume":"52","author":"Pijpe","year":"2005","journal-title":"Arthritis Rheum"},{"key":"2025042214240315100_keae152-B276","first-page":"88","article-title":"Rituximab therapy for systemic manifestations and MALT lymphomas of the parotid gland in Sjogren's disease: preliminary data","volume":"84","author":"Logvinenko","year":"2012","journal-title":"Terapevticheskii arkhiv"},{"key":"2025042214240315100_keae152-B277","first-page":"210","article-title":"Successful treatment with rituximab in a patient with primary thymic MALT lymphoma complicated with acquired von Willebrand syndrome and Sjogren syndrome","volume":"52","author":"Iwabuchi","year":"2011","journal-title":"[Rinsho ketsueki] Jap J Clin Hematol"},{"key":"2025042214240315100_keae152-B278","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/ard.2006.057919","article-title":"Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjogren's syndrome","volume":"66","author":"Seror","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"2025042214240315100_keae152-B279","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s00296-007-0396-4","article-title":"Successful treatment with rituximab in a patient with mental nerve neuropathy in primary Sjogren's syndrome","volume":"28","author":"Seve","year":"2007","journal-title":"Rheumatol Int"},{"key":"2025042214240315100_keae152-B280","first-page":"37","article-title":"The efficacy and safety of low-dose rituximab in treatment of primary Sjogren's syndrome with thrombocytopenia","volume":"51","author":"Zhou","year":"2012","journal-title":"Zhonghua nei ke za zhi"},{"key":"2025042214240315100_keae152-B281","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MD.0b013e31824125e4","article-title":"Prognosis and outcome of non-Hodgkin lymphoma in primary Sjogren syndrome","volume":"91","author":"Voulgarelis","year":"2012","journal-title":"Medicine"},{"key":"2025042214240315100_keae152-B282","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1136\/annrheumdis-2011-200086","article-title":"Efficacy of rituximab in primary Sjogren's syndrome with peripheral nervous system involvement: results from the AIR registry","volume":"71","author":"Mekinian","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"2025042214240315100_keae152-B283","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.3899\/jrheum.110077","article-title":"Treatment of mucosa-associated lymphoid tissue lymphoma in Sjogren's syndrome: a retrospective clinical study","volume":"38","author":"Pollard","year":"2011","journal-title":"J Rheumatol"},{"key":"2025042214240315100_keae152-B284","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1177\/0961203307078201","article-title":"Successful treatment of refractory neuroSjogren with Rituximab","volume":"16","author":"Yamout","year":"2007","journal-title":"Lupus"},{"key":"2025042214240315100_keae152-B285","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/mus.20664","article-title":"Rituximab treatment in patients with IVIg-dependent immune polyneuropathy: a prospective pilot trial","volume":"35","author":"Gorson","year":"2007","journal-title":"Muscle Nerve"},{"key":"2025042214240315100_keae152-B286","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.pulmoe.2021.06.004","article-title":"Rituximab for the treatment of acute onset Interstitial Lung Disease in primary Sjogren's syndrome","volume":"27","author":"Klinowski","year":"2021","journal-title":"Pulmonology"},{"key":"2025042214240315100_keae152-B287","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1136\/ard.2007.083865","article-title":"Reduction of fatigue in Sjogren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study","volume":"67","author":"Dass","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"2025042214240315100_keae152-B288","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1002\/art.27314","article-title":"Effectiveness of rituximab treatment in primary Sjogren's syndrome: a randomized, double-blind, placebo-controlled trial","volume":"62","author":"Meijer","year":"2010","journal-title":"Arthritis Rheum"},{"key":"2025042214240315100_keae152-B289","doi-asserted-by":"crossref","first-page":"233","DOI":"10.7326\/M13-1085","article-title":"Treatment of primary Sjogren syndrome with rituximab: a randomized trial","volume":"160","author":"Devauchelle-Pensec","year":"2014","journal-title":"Annals of internal medicine"},{"key":"2025042214240315100_keae152-B290","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1002\/art.40093","article-title":"Randomized controlled trial of rituximab and cost-effectiveness analysis in treating fatigue and oral dryness in primary Sjogren's syndrome","volume":"69","author":"Bowman","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2025042214240315100_keae152-B291","doi-asserted-by":"crossref","first-page":"e0150749-e","DOI":"10.1371\/journal.pone.0150749","article-title":"Rituximab Effectiveness and Safety for Treating Primary Sj\u00f6gren's Syndrome (pSS): systematic Review and Meta-Analysis","volume":"11","author":"Souza","year":"2016","journal-title":"PLoS One"},{"key":"2025042214240315100_keae152-B292","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jbspin.2017.06.004","article-title":"Efficacy and Safety of biological DMARDs modulating B cells in Primary Sjogren's syndrome: systematic review and meta-analysis","volume":"85","author":"Letaief","year":"2018","journal-title":"Joint Bone Spine"},{"key":"2025042214240315100_keae152-B293","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1136\/annrheumdis-2012-202293","article-title":"Efficacy of rituximab in systemic manifestations of primary Sjogren's syndrome: results in 78 patients of the AutoImmune and Rituximab registry","volume":"72","author":"Gottenberg","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2025042214240315100_keae152-B294","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1136\/annrheumdis-2019-eular.3098","article-title":"OP0202 effect of RSLV-132 on fatigue in patients with primary Sj\u00f6gren\u2019s syndrome\u2014results of a phase II randomised, double-blind, placebo-controlled, proof of concept study","volume":"78(Suppl 2)","author":"Fisher","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2025042214240315100_keae152-B295","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1002\/acr.20495","article-title":"Experience of intravenous immunoglobulin therapy in neuropathy associated with primary Sjogren's syndrome: a national multicentric retrospective study","volume":"63","author":"Rist","year":"2011","journal-title":"Arthritis Care Res"},{"key":"2025042214240315100_keae152-B296","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jns.2008.12.018","article-title":"Intravenous immunoglobulin treatment for painful sensory neuropathy associated with Sjogren's syndrome","volume":"279","author":"Morozumi","year":"2009","journal-title":"J Neurol Sci"},{"key":"2025042214240315100_keae152-B297","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1007\/s10067-003-0852-9","article-title":"Hypergammaglobulinemic purpura in two sisters with Sjogren's syndrome responding to colchicine treatment","volume":"23","author":"Habib","year":"2004","journal-title":"Clin Rheumatol"},{"key":"2025042214240315100_keae152-B298","first-page":"324","article-title":"Colchicine as possible treatment of non-cryoglobulinaemic vasculitis in Sj\u00f6gren's syndrome","volume":"38(Suppl 126)","author":"La Barbera","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"2025042214240315100_keae152-B299","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1001\/archderm.144.6.815","article-title":"Granulomatous panniculitis associated with Sjogren syndrome","volume":"144","author":"Chandrupatla","year":"2008","journal-title":"Arch Dermatol"},{"key":"2025042214240315100_keae152-B300","first-page":"25","article-title":"Recurrent acute idiopathic pericarditis: rheumatologic therapy, autoantibodies and long term outcome","volume":"59","author":"Brambilla","year":"2007","journal-title":"Reumatismo"},{"key":"2025042214240315100_keae152-B301","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ijporl.2018.07.002","article-title":"Juvenile recurrent parotitis: a systematic review of treatment studies","volume":"112","author":"Garavello","year":"2018","journal-title":"Int J Pediatr Otorhinolaryngol"},{"key":"2025042214240315100_keae152-B302","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s00405-021-06928-w","article-title":"Treatment of juvenile recurrent parotitis with irrigation therapy without anesthesia","volume":"279","author":"Geisthoff","year":"2022","journal-title":"Eur Arch Oto-Rhino-Laryngol"},{"key":"2025042214240315100_keae152-B303","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/acr.23264","article-title":"Natural history and predictors of progression to Sj\u00f6gren's syndrome among participants of the Sj\u00f6gren's International Collaborative Clinical Alliance Registry","volume":"70","author":"Shiboski","year":"2018","journal-title":"Arthritis Care Res"},{"key":"2025042214240315100_keae152-B304","doi-asserted-by":"crossref","first-page":"857014","DOI":"10.3389\/fimmu.2022.857014","article-title":"The shared mechanism and candidate drugs of multiple sclerosis and Sj\u00f6gren\u2019s syndrome analyzed by bioinformatics based on GWAS and transcriptome data","volume":"13","author":"Hong","year":"2022","journal-title":"Front Immunol"},{"key":"2025042214240315100_keae152-B305","first-page":"73","article-title":"Compromised ultrasound remission, functional ability and clinical decision associated with overlapping Sj\u00f6gren's syndrome in rheumatoid arthritis patients: results from a propensity-score matched cohort from 2009 to 2019","volume":"38(Suppl 126)","author":"Zhang","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"2025042214240315100_keae152-B306","doi-asserted-by":"crossref","first-page":"865","DOI":"10.3899\/jrheum.190250","article-title":"Sj\u00f6gren syndrome in systemic lupus erythematosus: a subset characterized by a systemic inflammatory state","volume":"47","author":"Ruacho","year":"2020","journal-title":"J Rheumatol"},{"key":"2025042214240315100_keae152-B307","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.semarthrit.2020.10.009","article-title":"Systemic sclerosis overlap and non-overlap syndromes share clinical characteristics but differ in prognosis and treatments","volume":"51","author":"Scherlinger","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"2025042214240315100_keae152-B308","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s10067-011-1789-z","article-title":"Clinical significance and diagnostic usefulness of anti-centromere antibody in Sj\u00f6gren\u2019s syndrome","volume":"31","author":"Kitagawa","year":"2012","journal-title":"Clin Rheumatol"},{"key":"2025042214240315100_keae152-B309","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.3390\/nu13061998","article-title":"A review of topical and systemic vitamin supplementation in ocular surface diseases","volume":"13","author":"Fogagnolo","year":"2021","journal-title":"Nutrients"},{"key":"2025042214240315100_keae152-B310","first-page":"216","article-title":"Mediterranean diet and risk of Sj\u00f6gren's syndrome","volume":"38(Suppl 126)","author":"Machowicz","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"2025042214240315100_keae152-B311","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/aos.14892","article-title":"Oxidative and antioxidative stress markers in dry eye disease: a systematic review and meta-analysis","volume":"100","author":"Navel","year":"2022","journal-title":"Acta Ophthalmol"},{"key":"2025042214240315100_keae152-B312","first-page":"34","article-title":"Omega-3 and omega-6 fatty acids in primary Sj\u00f6gren's syndrome: clinical meaning and association with inflammation","volume":"38(Suppl 126)","author":"Castrej\u00f3n-Morales","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"2025042214240315100_keae152-B313","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1056\/NEJMoa1709691","article-title":"n-3 fatty acid supplementation for the treatment of dry eye disease","volume":"378","author":"Asbell","year":"2018","journal-title":"N Engl J Med"},{"key":"2025042214240315100_keae152-B314","first-page":"CD011016","article-title":"Omega-3 and omega-6 polyunsaturated fatty acids for dry eye disease","volume":"12","author":"Downie","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"2025042214240315100_keae152-B315","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/ICO.0000000000001884","article-title":"Efficacy of omega-3 fatty acid supplementation for treatment of dry eye disease: a meta-analysis of randomized clinical trials","volume":"38","author":"Giannaccare","year":"2019","journal-title":"Cornea"},{"key":"2025042214240315100_keae152-B316","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jtos.2019.08.002","article-title":"The Dry Eye Assessment and Management (DREAM) extension study\u2014a randomized clinical trial of withdrawal of supplementation with omega-3 fatty acid in patients with dry eye disease","volume":"18","author":"Hussain","year":"2020","journal-title":"Ocular Surface"},{"key":"2025042214240315100_keae152-B317","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1093\/rheumatology\/kev227","article-title":"A systematic review of non-pharmacological interventions for primary Sjogren's syndrome","volume":"54","author":"Hackett","year":"2015","journal-title":"Rheumatology (Oxford, England)"},{"key":"2025042214240315100_keae152-B318","first-page":"77","article-title":"Managing fatigue in patients with primary Sjogren's syndrome: challenges and solutions","volume":"11","author":"Miyamoto","year":"2019","journal-title":"Open Access Rheumatol Res Rev"},{"key":"2025042214240315100_keae152-B319","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.brs.2020.12.004","article-title":"Transcranial direct current stimulation for fatigue in patients with Sjogren\u2019s syndrome: a randomized, double-blind pilot study","volume":"14","author":"Pinto","year":"2021","journal-title":"Brain Stimul"},{"key":"2025042214240315100_keae152-B320","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/ner.12879","article-title":"The effects of noninvasive vagus nerve stimulation on fatigue and immune responses in patients with primary Sj\u00f6gren's syndrome","volume":"22","author":"Tarn","year":"2019","journal-title":"Neuromodulation"},{"key":"2025042214240315100_keae152-B321","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.neurom.2022.08.461","article-title":"The effects of noninvasive vagus nerve stimulation on fatigue in participants with primary Sj\u00f6gren's syndrome","volume":"26","author":"Tarn","year":"2023","journal-title":"Neuromodulation"},{"key":"2025042214240315100_keae152-B322","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1080\/03009742.2019.1602880","article-title":"Effectiveness of resistance exercise in functional fitness in women with primary Sj\u00f6gren\u2019s syndrome: randomized clinical trial","volume":"49","author":"Minali","year":"2020","journal-title":"Scand J Rheumatol"},{"key":"2025042214240315100_keae152-B323","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s00296-018-4213-z","article-title":"Supervised walking improves cardiorespiratory fitness, exercise tolerance, and fatigue in women with primary Sj\u00f6gren's syndrome: a randomized-controlled trial","volume":"39","author":"Miyamoto","year":"2019","journal-title":"Rheumatol Int"},{"key":"2025042214240315100_keae152-B324","doi-asserted-by":"crossref","first-page":"719592","DOI":"10.3389\/fmed.2021.719592","article-title":"Cardiovascular effect of physical exercise on primary Sjogren's Syndrome (pSS): randomized Trial","volume":"8","author":"Garcia","year":"2021","journal-title":"Front Med"},{"key":"2025042214240315100_keae152-B325","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1136\/annrheumdis-2019-eular.7680","article-title":"AB1369-HPR the effects of clinical Pilates training in individuals with primary Sjogren\u2019s syndrome","volume":"78(Suppl 2)","author":"Aylin","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2025042214240315100_keae152-B326","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3390\/ijerph18010017","article-title":"Effect of a tailored activity pacing intervention on fatigue and physical activity behaviours in adults with multiple sclerosis","volume":"18","author":"Abonie","year":"2020","journal-title":"Int J Environ Res Public Health"},{"key":"2025042214240315100_keae152-B327","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1080\/02640414.2020.1721254","article-title":"Optimising activity pacing to promote a physically active lifestyle in medical settings: A narrative review informed by clinical and sports pacing research","volume":"38","author":"Abonie","year":"2020","journal-title":"Journal of sports sciences"},{"key":"2025042214240315100_keae152-B328","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1136\/annrheumdis-2018-213718","article-title":"Effect of in utero hydroxychloroquine exposure on the development of cutaneous neonatal lupus erythematosus","volume":"77","author":"Barsalou","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2025042214240315100_keae152-B329","doi-asserted-by":"crossref","first-page":"761.e1","DOI":"10.1016\/j.ajog.2022.05.071","article-title":"Reducing the burden of surveillance in pregnant women with no history of fetal atrioventricular block using the negative predictive value of anti-Ro\/SSA antibody titers","volume":"227","author":"Kaizer","year":"2022","journal-title":"Am J Obstetr Gynecol"},{"key":"2025042214240315100_keae152-B330","first-page":"95","article-title":"Autoimmune congenital heart block and primary Sj\u00f6gren's syndrome: characterisation and outcomes of 49 cases","volume":"38(Suppl 126)","author":"Brito-Zer\u00f3n","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"2025042214240315100_keae152-B331","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/nrrheum.2015.29","article-title":"The clinical spectrum of autoimmune congenital heart block","volume":"11","author":"Brito-Zeron","year":"2015","journal-title":"Nat Rev Rheumatol"},{"key":"2025042214240315100_keae152-B332","article-title":"P280\u2003Maternal use of hydroxychloroquine with anti-Ro and or anti-La during pregnancy: a systematic review","volume":"61(Suppl 1):i154","author":"Nokhatha","year":"2022","journal-title":"Rheumatology"},{"key":"2025042214240315100_keae152-B333","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.jacc.2020.05.045","article-title":"Hydroxychloroquine to prevent recurrent congenital heart block in fetuses of anti-SSA\/Ro-positive mothers","volume":"76","author":"Izmirly","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2025042214240315100_keae152-B334","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1111\/jog.14561","article-title":"Impact of hydroxychloroquine on the gestational outcomes of pregnant women with immune system problems that necessitate the use of the drug","volume":"47","author":"Beksac","year":"2021","journal-title":"J Obstetr Gynaecol Res"},{"key":"2025042214240315100_keae152-B335","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1016\/j.amepre.2021.01.032","article-title":"Aspirin prophylaxis during pregnancy: a systematic review and meta-analysis","volume":"61","author":"Choi","year":"2021","journal-title":"Am J Prev Med"},{"key":"2025042214240315100_keae152-B336","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s12026-016-8888-5","article-title":"Obstetric and perinatal outcome in anti-Ro\/SSA-positive pregnant women: a prospective cohort study","volume":"65","author":"Martinez-Sanchez","year":"2017","journal-title":"Immunol Res"},{"key":"2025042214240315100_keae152-B337","first-page":"706","article-title":"Plasmapheresis, intravenous immunoglobulins and bethametasone\u2014a combined protocol to treat autoimmune congenital heart block: a prospective cohort study","volume":"34","author":"Ruffatti","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"2025042214240315100_keae152-B338","doi-asserted-by":"crossref","first-page":"100072","DOI":"10.1016\/j.eurox.2019.100072","article-title":"Use of antenatal fluorinated corticosteroids in management of congenital heart block: systematic review and meta-analysis","volume":"4","author":"Michael","year":"2019","journal-title":"Eur J Obstetr Gynecol Reprod Biol X"},{"key":"2025042214240315100_keae152-B339","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1159\/000513202","article-title":"Effects of transplacental dexamethasone therapy on fetal immune-mediated complete heart block","volume":"48","author":"Saito","year":"2021","journal-title":"Fetal diagnosis and therapy"},{"key":"2025042214240315100_keae152-B340","doi-asserted-by":"crossref","first-page":"575","DOI":"10.55563\/clinexprheumatol\/7vp1bo","article-title":"Disease evolution in a long-term follow-up of 104 undifferentiated connective tissue disease patients","volume":"40","author":"Radin","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"2025042214240315100_keae152-B341","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13293-017-0146-6","article-title":"Long-term follow-up in primary Sj\u00f6gren's syndrome reveals differences in clinical presentation between female and male patients","volume":"8","author":"Ram\u00edrez Sep\u00falveda","year":"2017","journal-title":"Biol Sex Diff"},{"key":"2025042214240315100_keae152-B342","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1007\/s10067-022-06119-w","article-title":"A comprehensive overview of living with Sj\u00f6gren's: results of a National Sj\u00f6gren's Foundation survey","volume":"41","author":"McCoy","year":"2022","journal-title":"Clin Rheumatol"},{"key":"2025042214240315100_keae152-B343","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s40744-020-00220-9","article-title":"An innovative online qualitative study to explore the symptom experience of patients with primary Sj\u00f6gren's syndrome","volume":"7","author":"Gairy","year":"2020","journal-title":"Rheumatol Ther"},{"key":"2025042214240315100_keae152-B344","first-page":"175","article-title":"Sj\u00f6gren's syndrome towards precision medicine: the challenge of harmonisation and integration of cohorts","volume":"37(Suppl 118)","author":"Goules","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"2025042214240315100_keae152-B345","author":"Hackett"},{"key":"2025042214240315100_keae152-B346","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/odi.12404","article-title":"Is Youtube useful as a source of information for Sj\u00f6gren's syndrome?","volume":"22","author":"Delli","year":"2016","journal-title":"Oral Dis"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keae152\/57236552\/keae152.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/2\/409\/57236552\/keae152.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/2\/409\/57236552\/keae152.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T18:24:58Z","timestamp":1745346298000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/64\/2\/409\/7645909"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,16]]},"references-count":346,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,4,16]]},"published-print":{"date-parts":[[2025,2,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keae152","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,2]]},"published":{"date-parts":[[2024,4,16]]}}}